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Abstract 
Human constitutive androstane receptor (hCAR, NR1I3) is a member of nuclear receptor 
superfamily. It functions as a key regulator of the metabolism for a variety of xenobiotics, 
steroid hormones, bile acids, etc. The co-regulator proteins are indispensable for above 
functions that are mediated by hCAR. There is usually more than one short length peptide 
within one co-regulator. These peptides are called nuclear receptor interaction motifs, 
which are essential for the direct interaction between co-regulator and nuclear receptor 
(NR). Previous studies suggest that the position of C-terminal helix (H12) of the NRs 
ligand binding domain (LBD) is a key element that influences such interaction. In co-
activators and mediator, the motifs usually share a conserved LXXLL sequence, while the 
motifs in co-repressors commonly share a longer sequence which is LXXXI/LXXXI/L. A 
nuclear receptor can specifically bind to these motifs, and display differential recruitment 
among several motifs in one co-regulator molecule. To understand such specificity of 
hCAR, the interaction between hCAR-LBD and a series of co-regulator motifs were 
analyzed in this study using 9 molecular dynamics (MD) simulation systems. The systems 
consisted of apo/liganded hCAR-LBD and the co-regulator peptide. Due to lack of 
information about the crystal structures of the studied co-regulator peptides, homology 
models were used to generate these structures. Analysis on the trajectories from MD 
simulations and the corresponding final structures suggested that co-repressor peptides 
were able to induce significant structural changes of hCAR-LBD, whereas the co-activator 
and mediator peptides only changed the structures subtly. The structural changes at C-
terminus of hCAR-LBD and the binding behavior of peptides onto the co-regulator groove 
indicated that, peptide containing ID2 of NCoR may be responsible for the reorientation of 
H12 in the presence of inverse agonists. Thus ID2 could be an important motif for the 
repressive control of hCAR via co-repressor NCoR. For the co-activators and mediator 
investigated in this work, peptide containing NR1 and NR2 of SRC-1 and NR2 of TRAP 
may help to maintain the active form of H12 and HX. Therefore, they could also be critical 
motifs for hCAR-dependent gene regulation by SRC-1 or mediator.    
Key words: nuclear receptor, hCAR, molecular dynamics, co-regulator, NCoR, SRC-1, 
agonist, inverse agonist  
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1 Introduction  
 
1.1 Classification, structure and function of nuclear receptors 
 
Nuclear receptors (NRs) are ligand-regulated transcription factors (TFs) that respond to an input 
(such as steroids, retinoids, bile acids, heme, xenobiotics) and produce an output (such as gene 
expression or repression) (Aagaard et al., 2011; Huang et al., 2010; Sladek, 2010; Privalsky, 
2004). NRs play an essential role in the regulation of cell differentiation, development, 
reproduction, metabolism and homeostasis in multi-cellular organisms (Li and Wang., 2010; 
Perssi and Rosenfeld, 2005; Gronemeyer et al., 2004; Nagy and Schwabe, 2004). The 
inappropriate function of NR impacts a wide range of pathophysiologies ranging from cancer to 
metabolic diseases (Trauner et al., 2011; Huang et al., 2010; Khan and Lingrel et al., 2010; 
Gronemeyer et al., 2004).  
NRs bind to their target DNA sequences as homo- or hetero-dimers. In general, NRs regulate 
gene expression in a ligand-dependent manner. Some of the NRs, such as constitutive androstane 
receptor (CAR) can also regulate gene expression in the absence of ligand. NR-mediated gene 
expression is through stepwise and ordered recruitment of various transcription complexes which 
contain transcription co-regulators (Germain et al., 2006). For decades, the structure and function 
of NRs have been the targets of research and drug design (Huang et al., 2010; Germain et al., 
2006; Mangeldorf et al., 1995).  
 
The sequencing of the human genome has led to the identification of 48 NRs, which can be 
classified into six evolutionary groups. This classification is based on sequence alignment and 
phylogenetic tree construction of highly conserved domains (Nuclear Receptor Nomenclature 
Committee, 1999). The phylogenetic position of each NR is relevant to the DNA -binding and its 
dimerization abilities (Germain et al., 2006). Alternatively, based on the ligand-binding 
specificities, NR superfamily can also be divided into three classes: classic receptors, orphan 
receptors and adopted orphan receptors (Jin and Li., 2010). Classic receptors, such as androgen 
receptor (AR) and estrogen receptor (ER), are regulated by endocrine ligands. The receptors 
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without endogenous ligands are identified as orphan receptors, such as small hetero-dimer partner 
(SHP), estrogen related receptors (ERRs) and hepatocyte nuclear factor α (HNFα). Since the 
physiological ligands have been identified for orphan receptors, those receptors are thus classified 
as adopted orphan receptors. CAR is assigned into this class. 
 
In addition, isoforms (products from alternative transcription start sites on the same gene and 
products of mRNA splice variants) and subtypes (products of closely related genes) are known 
for most NRs (Germain et al., 2006). These isoforms and subtypes of NRs differ in the regard of 
ligand binding affinity, transcription activity and distribution in cell and tissues, which contribute 
complexity for the NR-mediated regulation network (Germain et al, 2004; Steinmetz et al., 2001; 
Katzenellenbogen et al., 1996). 
 
Figure 1. General structure of nuclear receptors (Aagaard et al., 2011). 
 
All NRs share high sequence similarity and conserved domains (Jin and Li., 2010). Typically, a 
NR consists of five functional regions (Fig 1). These regions are designated as N-terminal 
domain (NTD or A/B domain), DNA binding domain (DBD or C domain), ligand binding 
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domain (LBD or E domain), a highly variable hinge region between DBD and LBD (or D 
domain). The importance and the structural properties of these domains are discussed below.  
 
N-terminal domain and Hinge region  
These two domains are less conserved compared to DBD and LBD. To date, no crystal structure 
of NTD has been resolved. This may due to the flexible nature of NTD (Jin and Li., 2010). NTD 
contains a ligand-independent transactivation function, called activation function 1 (AF1). 
Among different receptors, AF-1 exhibits distinct structural features and different functions. For 
example, AF-1 is responsible for the transactivation in the case of AR (Simental et al., 1991), 
whereas the function of AF-1 could be limited in CAR since it has a very narrow NTD region 
(Baes et al., 1994). The hinge region D is also poorly conserved and little is known about its 
structure. It confers the spatial flexibility to the receptors (Aagaard et al., 2011). Moreover, it is 
reported that this region may harbor nuclear localization signals (Germain et al., 2006). 
 
DNA binding domain 
DBD is the most conserved domain. With this domain, NRs bind to specific DNA sequences, 
called hormone response elements (REs). The core region of this domain is composed by 
approximate 66 amino acids (Aagaard et al., 2011; Aranda and pascual, 2001). These amino acids 
fold into a globular domain and are made up of two characteristic cysteine-rich zinc finger motifs 
(Bain et al., 2007). These two zinc-finger motifs are critical in stabilizing the overall folding of 
DBD and its DNA-binding activity. Besides the zinc-finger motifs, there are two perpendicular α-
helices in this domain: the N-terminal helix (helix I) and the C-terminal helix (helix II) (Bain et 
al., 2007). Helix I, termed as the recognition helix, locates between the two zinc-finger motifs 
and interacts with DNA in a sequence-dependent manner. This helix contains a P box, which is 
defined by residues that are important for sequence-specific DNA binding. On the other hand, 
helix II contributes to non-specific backbone interactions with DNA (Aagaard et al., 2011). For 
some NRs, helix II contains the D-box, which is involved in dimerization (Aagaard et al., 2011; 
Jin and Li, 2010). DBD also harbors the nuclear translocation signals (Germain et al., 2006). And 
this domain also constitute the dimer interface with the dimer partners (Jin and Li., 2010).  
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Ligand binding domain 
LBD is the second conserved domain of NRs. Numerous crystal structures of NR-LBDs indicate 
that this domain consists of 11- 13 α helices and 2 – 4 β sheets. These secondary elements are 
arranged in three layers in tertiary structure and form an anti-parallel α-helical ‘sandwich’ (Jin 
and Li, 2010).  
Based on the highly organized and well-defined structures, LBD has a number of critical 
functions. First, it provides a ligand binding pocket (LBP) for endogenous and exdogenous 
ligands. The LBP locates in the interior of this domain and is formed by a subset of surrounding 
residues from helices 3, 5, 6, 7, 10 and β-sheets (Steinmetz et al., 2001). The size of the LBP 
depends on the type of the NRs and the bound ligand. Due to the hydrophobic nature of the LBP, 
the ligand binding largely relies on hydrophobic interactions (Jin and Li., 2010; Bain et al., 2007). 
However, some orphan receptors may lack of LBP (e.g. nuclear receptor related 1 protein, so 
called Nurr1, see Wang et al., 2003) or lack of entry point for cavity (e.g. liver receptor homolog-
1 or so-called LRH-1, see Sablin et al., 2003). These orphan receptors may function in an 
alternative way by being ligand-independent. Second, LBD contains an activation function 2 
(AF-2) at helix 12 (H12). In contrast to AF-1, the function of AF-2 is ligand-dependent and is 
crucial for co-regulator recruitments. Third, LBD can interact with the co-regulators. This domain 
contains the site for co-regulator binding, namely "co-regulator groove". The groove mainly 
involves residues from helices 3, 4, and 12. Forth, LBD provides a NR-NR dimerization surface 
for NRs which function as dimers (Aagaard et al., 2011, Bain et al., 2007).  
 
1.2 Constitutive androstane receptor  
 
1.2.1  Physiological role of CAR  
 
CAR (NR1I3) is a member of NR1I subfamily, which regulates a large set of genes. The classic 
CAR-regulated genes encode drug-metabolizing enzymes, including phase I cytochromes 
enzymes, phase II UDP-glucuronosyl transferase, sulfotransferases and multiple transporter 
proteins (Tolson and Wang., 2010). These enzymes are important in the elimination of 
xenobiotics. In this context, CAR was firstly recognized as a sensor of xenobiotics, such as drugs 
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and environmental pollutants. However, in recent years, CAR has been intensively studied due to 
its significance on a variety of physiological functions (Kachaylo et al., 2011; Masi et al., 2009). 
For example, CAR mediates the effect of hormonal signals and regulates the detoxification and 
excretion of toxic endogenous metabolites such as bilirubin and bile acids (Masi et al., 2009; 
Qatanani et al., 2005). Moreover, CAR is also involved in lipid metabolism and glucose 
homeostasis (Kachaylo et al., 2011). Based on the diversity of its functions, hCAR is considered 
not only as an interesting subject of research because of its role in the regulation of drug 
metabolism, but also a potential drug target for the prevention and treatment of many diseases, 
especially metabolic-related diseases, such as hepatocelluar carcinoma (Sberna et al., 2011; 
Dussault et al., 2002).  
 
Unlike classical NRs, CAR is in active state when no ligands bind into the LBP. This feature is 
termed as constitutive activity (Windshügel et al., 2005; Xu et al., 2004; Frank et al., 2004; 
Dussault et al., 2002). Two endogenous ligands of hCAR, androstanol and androstenol (ANDR), 
were found to repress the constitutive activity of CAR. In addition, many xenobiotics, including 
synthetic compounds display differential effects on CAR-dependent gene regulation by activating 
or repressing it (Li et al., 2008; Maglich et al., 2003; Tzameli et al., 2000). 
 
CAR is expressed primarily in liver and kidney (Kachaylo et al., 2011). In absence of ligand, it 
predominantly locates in cytoplasm, and forms complex with other proteins, such as heat shock 
protein (HSP90), cytoplasmic hCAR-retention protein (CCPR) and the membrane-associated 
subunit of protein phosphatase 1β (PPP1R16A). Upon ligand binding, human (hCAR) is 
dephosphorylated, which is followed by its dissociation from the cytoplasmic complex and 
translocation into the nucleus (Kachaylo et al., 2011; Mutoh et al., 2009). The interference which 
affects the translocation would also affect the activity of CAR. Subsequent to translocation, CAR 
forms a hetero-dimer with retinoid X receptor (RXRα), which then binds to the promoter region 
of the target gene with DBD (Frank et al., 2003). By interacting with multiple protein complexes 
(such as co-activator complex, polymerase II complex), the expression of the target gene is 
activated.  
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1.2.2  Structural features of CAR  
 
Like other NRs, CAR contains five functional regions; the x-ray crystal structure is only 
available for its LBD. As mentioned above, the N-terminus of CAR is short in length and 
insignificant in function of AF-1 (Jin and Li., 2010). However, this domain is potentially 
involved in post-translational modifications (PTMs) and tissue specific activity. Yet the 
mechanism is not clearly understood (Kachaylo et al., 2011). The hinge region is responsible for 
rotation of DBD in relative to the position of LBD. DBD domain of CAR, as other NRs, also 
appears in a globular shape and contains two α-helices perpendicular to one another (Masi et al., 
2009). It would also be of great importance to the understanding of CAR function if both DBD 
and LBD were crystallized together, like for peroxisome proliferator-activated receptor-gamma 
(PPARγ) (Chandra et al.,2008).  
 
LBD (amino acids 103-348) is composed of 11 α-helices, two 310 helices (designated H2 and H2’) 
and three β-sheets (Xu et al., 2004). In other NRs, helix 10 links to H12 via a flexible loop; but in 
the case of hCAR, the loop is replaced by a single-turn helix, called HX. Due to the rigidity of 
HX, the conformational freedom of H12/AF-2 is effectively limited. Thus HX is regarded as 
potentially important for the constitutive activity of hCAR. The LBP is constituted of residues 
from helix 2 - 7 and helix 10 and β-sheets regions (Xu et al., 2004). CAR as a xenobiotics sensor 
has a quite flexible LBP with changeable shape and cavity volume, which enable CAR to 
accommodate a wide range of ligands (Masi et al., 2009). These ligands can be divided into 
agonists and inverse agonists, the former can further activate CAR, whereas the latter inhibit the 
basal transcriptional activity of CAR. This domain is also involved in hetero-dimerization, 
mainly using helix 10 to form a back-to-back hetero-dimer with RXRα (Xu et al., 2004). 
Importantly, LBD also plays an essential role in co-regulator recruitment, which largely 
determines the output of CAR-mediated gene expression, as discussed from sections 1.3 to 
section 1.5.   
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1.3 Nuclear receptor co-regulators 
 
1.3.1  Introduction to nuclear receptor co-regulators 
 
NRs modulate transcription through the interaction with co-regulators (O’Malley et al., 2008; 
Privalsky, 2004). Co-regulators include a large array of molecules, which are generally divided 
into co-activators, co-repressors and mediator. Co-activators are usually recruited by agonist 
bound NRs or constitutive active NRs. As the name suggested, co-activators are responsible for 
the transactivation of target genes. By contrast, co-repressors are usually recruited by ligand-free 
(apo) and antagonist or inverse agonists bound NRs, and they inhibit the gene expression. 
Mediator, on the other hand, can either activate or repress the gene expression by interacting with 
NRs directly or indirectly. Nevertheless, the role of each co-regulator is not fixed. In certain 
context, co-repressor can function as co-activator and vice versa (Santos et al., 2011; Kato et al., 
2011; Lonard and O’Malley., 2007).  
 
To date, there are more than 350 co-regulators that have been reported in the literature, 
suggesting their critical role in the transcriptional regulation (York and O’Malley., 2010). In fact, 
many co-regulators work together by forming multi-component protein complexes. The 
composition of regulatory complexes is subject to dynamic rearrangements in a spatial and 
temporal manner (Kato et al., 2011; Lonard and O’Malley., 2007; Perssi and Rosenfeld., 2005). 
 
Comparable to ‘histone code’, the co-regulators can also be differentially ‘coded’ via PTMs, such 
as phosphorylation, methylation, and acetylation. These modifications of co-regulators can be 
trigged by other co-regulators or multiple signaling cascade kinases. Recent studies suggested 
that each combination of such modifications is expected to have a distinct functional outcome 
(e.g. O’Malley et al., 2008; Lonard and O’Malley., 2007).This phenomenon is the so-called ‘co-
regulator codes’ (Lonard and O’Malley., 2007). ‘Co-regulator codes’ potentiate to integrate 
multiple cellular signals into the event of gene-specific transcription and is considered to play a 
vital role in the regulation of gene expression (O’Malley et al., 2008).  
These co-regulators are not exclusive to NRs; they also intensively participate in other non-NR 
signal transduction pathways. This feature of co-regulators has further complicate the NR 
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regulation network (Perssi and Rosenfeld., 2005). Being closely involved in the gene regulation 
network, the dysfunction of co-regulators can often cause physiological abnormalities and 
diseases (Hsia et al., 2010).  
 
1.3.2  Co-regulator regulated transcription 
 
Transcription, a key biological process, is the first step of gene expression. Transcription consists 
of multiple sub-reactions occurring in a specific order. Due to multiple molecules or complexes 
are needed in this process, transcription can be strongly influenced by many factors. In the case 
of NR-mediated gene expression, such factors mainly arise from two aspects: the chromatin 
environment that surrounds the genes and the availability of RNA polymerase II holo-complex 
(Lonard and O’Malley., 2007). Thus most of the co-regulators are able to affect these two critical 
factors/conditions. On one hand, many co-regulators tether varied enzymatic activities to the 
transcriptional complex in order to modify the configuration of chromatin. One the other hand, 
some co-regulators also serve as bridging agents to connect the receptor to basal transcriptional 
machinery (including RNA polymerase II holo-complex) for the purpose of regulating target 
gene expression, such as the mediator.  
 
DNA molecules are packed into a histone protein/DNA structure. The structure is termed 
chromatin (Hsieh and Fischer., 2005). The compact form of chromatin usually hinders the 
assembly of transcription complexes and result in the repression of transcription. In case of a 
more open form of chromatin configuration, the transcription would be allowed to process 
actively. In order to change the active state of chromatin structure, there are a lot of co-regulators 
that participate in the reorganization of chromatin structures. Based on their different mechanisms, 
these co-regulators are divided into three groups: chromatin remodelers, histone chaperones and 
histone modifiers (Kato et al., 2011).  
 
The chromatin configuration can be modified via the recruitment of chromatin remodeler 
complexes into the promoter region of target gene (Wolf et al., 2008). Among the reported 
chromatin remodeling complexes, switch/sucrose non-fermenting (SWI/SNF) complex and 
imitation switch (ISWI) complex can both activate and repress the chromatin state, whereas Mi2-
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type complex appears to repress the chromatin only (Kato et al., 2011). Some subunits within 
these complexes may direct interact with NRs, and be of great importance by controlling the 
accessibility of other co-regulators or complexes (Kato et al., 2011).  
 
Histone chaperones, the key actors during histone metabolism, consistently contribute to histone 
assembly, replacements and exchanges (Koning et al., 2007). By regulating the behavior of 
histones, histone chaperones are thus able to reorganized the chromatin configuration and affect 
the functional outcomes of NRs. Hence, histone chaperones can also be classified as co-
regulators (Kato et al., 2011).  
 
Based on the hypothesis of histone code, the chromatin configuration is directed by specific 
combinations of histone modifications (Jenuwein and Allis., 2001). Thus such modification of 
histone proteins would ultimately allow or block gene expression (Wolf et al., 2008; Glass et al., 
1997). Among the reported histone modifications, the histone acetylation is most studied and 
clearly linked to chromatin activity and transcriptional regulation (Kato et al., 2011). The 
modification is mainly executed by two types of enzymes: histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). HATs are enzymes which add the acetyl group to histones, 
whereas HDACs remove it. By histone acetylation, HATs enhance the target gene accessibility to 
transcription complex and facilitate the target gene transactivation. On the other hand, by histone 
deacetylation, HDACs pack the chromatin state tightly and repress of transactivation 
(Honkakoski and Negishi, 2000). Therefore, HATs are usually included in the co-activator 
complexes (such as SRCs and CBP/p300 co-activators), whereas HDACs usually form the core 
subunit of co-repressor complexes (Kato et al., 2011; Guo et al., 2012; Watson et al., 2012). By 
contrast to the co-regulators that hold HAT or HDAC activities, mediator is less involved in 
chromatin modifications via histone modifications. Instead, it may function at different steps by 
introducing the basal transcription machinery to the transcriptional complex that generated by 
NRs and other co-regulators (Chen and Roeder., 2011; Wärnmark et al., 2001).  
 
NR-mediated gene regulation is a network composed of multiple factors. These factors, as well as 
all the co-regulators, could be targets of other signaling cascades. This phenomenon is termed as 
crosstalk. To date, such crosstalk is assumed to occur in at least three ways (Gronemeyer et al., 
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2004): (1) interference between NRs and other TFs (Aagaard et al., 2011). For instance, the 
chromatin modification factors recruited by NRs can either enhance or repress the transcriptional 
activity of other TFs, who share the same binding profiles with the NRs, (2) PTMs of either NRs 
or co-regulators. These modifications are of great importance on the activity of NRs and co-
regulators. Hence, the factors acting on kinases can also modulate NR activity in ligand-
independent manner, (3) ‘no-genomic’ actions of NRs in ligand-dependent or independent 
manner (Germain et al., 2006; Gronemeyer et al., 2004).  
 
1.3.3  Co-activators 
 
The SRC family members (SRCs) of co-activators are usually one of the first recruited co-
activators by active NRs (Germain et al., 2006). The family members include SRC-1, SRC-
1/GRIP1/TIF2, and SRC-3/pCIP/ACTR/AIB1/RAC-3/TRAM-1. These three co-activators 
mediate the transcription of many genes as a response to a single molecular event and are 
extensively involved in diverse physiological processes (York and O’Malley., 2010). 
 
SRCs are approximate 160 kDa in size and share 50-55% sequence similarity (Chen et al., 2011). 
Their crystal structures of full-length sequence are currently not available. Both biological and 
structural studies have suggested that SRCs share five fundamental and structurally conserved 
domains (Chen et al., 2011), which include: (1) N-terminal bHLH/PAS (basic helix-loop-helix-
per/ARNT/sim) domain. This domain is highly conserved and mainly responsible for the 
interaction of SRCs with other co-regulators. In addition, the nuclear localization signals are 
believed to locate in this domain. Thus this domain is also critical in directing the distribution and 
localization of SRCs; (2) Serine/threonine (S/T)-rich domain. This domain is the popular target 
for PTMs. These modifications would probably produce differential biological consequences by 
affecting the localization, activity, stability of SRCs; (3) nuclear receptor interacting domain 
(RID). In the context of NR-mediated gene regulation, this domain is responsible for direct 
interaction with the NRs; (4) CBP/p300 interaction domain (CID), is also called activation 
domain 1 (AD1). AD1 can bind to CBP/p300 and activate the chromatin configuration by histone 
acetylation; (5) Histone acetyltransferase (HAT) domain or activation domain 2 (AD2). AD2 can 
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bind to CARM1 (co-activator-associated arginine methyl-transferase) and PRMT1 and enhanced 
the activation of chromatin by promoting histone methylations. 
 
Beside SRCs, a large number of co-activators have been identified and characterized over years 
(Thakur and Paramanik., 2009). These co-activators appear to be involved in almost every 
aspects of gene regulation. For example, in addition to transcription initiation, these co-regulators 
also play a part in the process of mRNA elongation, splicing, even translation (O’Malley et al., 
2008). The functional studies of RID of SRCs, combing the crystal structures of activated LBDs 
that co-crystallized with short peptides co-activators, an important motif has been discovered. 
The motif is termed as NR box, and it has the consensus sequence LXXLL, where L represents 
leucine and X means any amino acids. These NR-boxes are used by co-activators to directly 
interact with the NRs.   
Interestingly, NCoR which commonly appears as co-repressor can also act as co-activator under 
specific conditions. For example, NCoR was seen to directly associate with co-activator ACTR, 
and assist the transcriptional activation of thyroid hormone receptor β (TR β) mediated genes (Li 
et al., 2002).     
   
1.3.4  Co-repressors 
 
Nuclear receptor co-repressor (NCoR) (Hörlein et al., 1995) and silencing mediator for retinoid 
and thyroid hormone receptors (SMRT) (Chen and Evans, 1995) play an important role in NR 
transcription repression (Privalsky, 2004; Hsia et al., 2010). Studies on NCoR and SMRT 
homology domains suggested that they share high sequence similarity and conserved molecular 
architecture, as well as similar function mechanisms (Privalsky, 2004; Ordentlich et al., 1998; 
Perissi et al., 1999). 
 
NCoR includes three repression domains (RDs) at N-terminus and three nuclear receptor 
interaction domain (IDs) at C-terminus, while SMRT includes four RDs at N-terminus and two 
IDs at C-terminus (Privalsky., 2004). The highly conserved RDs mostly serve as the docking 
platforms for secondary co-repressors (i.e. other components of the large co-repressor complex, 
12 
 
such as HADCs) to bind either sequentially or simultaneously (Privalsky, 2004). IDs are 
responsible for the interaction with NRs (Privalsky, 2004; Perissi et al., 1999). 
 
Among the multiple proteins recruited by SMRT and NCoR, HADCs are best characterized and 
well known for their activity of chromatin condensation. The secondary co-repressors recruited 
by NCoR and SMRT also include TBL-1 (transducin-like protein 1), TBL1-R (TBL-1-related 
protein), GPS2 (G protein pathway suppressor 2) and mSin3 (mammalian switch-independent 3 
proteins). It has been proposed that these secondary co-repressors may function as scaffolds or 
assist in repression via distinct mechanisms (Privalsky, 2004). However, the molecular basis for 
such interactions is still largely unknown. Some indirect evidences also imply that solely SMRT 
or NCoR binding to NR is not be sufficient for the inactivation of transcription, instead, 
transcription repression complexes which include multiple co-repressors are needed (Privalsky, 
2004).   
 
Co-repressors interact with NRs using IDs which have conserved sequence of I/LXXII (where I 
is isoleucine, X is any residue (Nagy et al, 1999; Hu and Lazar, 1999; Webb et al., 2000; Perssi 
and Rosenfeld, 2005) or LXXXI/LXXXI/L (Perissi et al., 1999; Xu et al., 2002). The interaction 
between the co-repressors (e.g. NCoR and SMRT) and the NRs is based on the binding of these 
motifs onto the co-regulator groove of NR-LBDs. The binding site of co-repressor IDs with NRs 
is partially overlapping with the binding site of co-activator NR boxes (Xu et al., 2002). 
 
A new group of co-repressors has been found to interact with agonist bound NRs using LXXLL 
motifs (Gurevich et al., 2007). This group includes receptor-interacting protein 140 (RIP140), 
ligand-dependent co-repressor (LCoR), repressor of estrogen activity (REA) and metastasis 
associated factor (MTA), etc. Within this group, some co-repressors only contain RDs and 
mediate gene silencing by HDACs recruitment, but others may also contain ADs, which bind to 
NRs as co-activators (Hsia et al., 2010).  
 
Surprisingly, NRs themselves can also be co-repressors, such as DAX-1 (dosage-sensitive sex 
reversal, adrenal hypoplasia critical region, on chromosome X, gene 1) and SHP, that act as 
inhibitory partner for other NRs (Germain et al., 2006).  
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1.3.5  Nuclear receptor mediator 
 
Mediator, so-called thyroid hormone receptor-associated protein (TRAP), plays an essential role 
in gene regulation by NRs and other TFs. The function of the mediator is based on its multiple 
subunits, which have distinct structures and functions. Recent researches (e.g. Malik and Roeder., 
2010) have revealed that the mediator is an ordered and sequentially assembled complex, and 
serves as a platform for other co-regulators. The components of a mediator complex are highly 
variable (Chen and Roeder., 2011). In general, a mediator complex usually consists of head, 
middle and tail modules. The middle and tail modules are linked by subunits such as MED1 and 
MED26 (Malik and Roeder., 2010).  
A mediator can have multiple functions. On one hand, the mediator can activate transcription and 
stimulate basal transcription. One the other hand, mediator can act as co-repressors and inactivate 
the transcription (Chen and Roeder., 2011). Different from many co-activators and co-repressors, 
mediator may link the general transcription machinery and RNA polymerase II in a direct way 
(Chen and Roeder., 2011). Moreover, mediator can recruit histone modifiers and chromatin 
remodelers, which reorganize the chromatin structure (Chen and Roeder., 2011). 
Among these subunits of mediator, MED1 is better characterized. The cell-based assays 
suggested that MED1 can interact with many NRs, including TR, ER, VDR, GR, retinoic acid 
receptor (RAR) and RXR. Known from the mouse model, MED1 is responsible for many 
important NR-regulated functions, such as the PPARγ mediated adipogenesis and CAR-mediated 
hepatic steatosis, etc. MED1 contains two LXXLL motifs. These two motifs also called NR 
boxes and are utilized to interact with NRs directly. Similar to what has seen in NR-co-activator 
interaction, the position of AF-2 can critically affect the interaction between NR boxes of MED1 
and NRs. However, NR boxes of mediator are not necessary for the in vivo function of NRs, 
which suggest alternative pathways for mediator to interact with the NRs and being LXXLL 
independently.  
Other subunits of mediator, such as MED14 can specifically interact with AF-1 of NRs, such as 
GR and PPARγ. Meanwhile, these NRs can also interact with MED1 through AF-2 domain. Such 
differential regulation is usually determined by the target genes or other factors (Chen and 
Roeder, 2011). MED25 contains one LXXLL motif and is found to directly associate with HNFα 
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and regulate a set of genes. MED15 can activate sterol regulatory element binding proteins -1 α 
(SREBP-1α) and regulate lipid homeostasis, through the recruitment of cofactors that include 
other mediator subunits and p300/CBP histone acetyltransferases. 
 
1.4 Influence of ligand binding on nuclear receptor structure and co-
regulator recruitment 
 
NR-mediated transcription is a chain of biological reactions, which is usually trigged by the 
binding of ligand into the LBP of the NRs.  By definition, agonists are ligands that lock the 
receptor in the active form and antagonists are ligands that prevent the receptor from adopting 
active conformation (Germain et al., 2006). Term inverse agonists, refers to antagonists, but is 
used specifically for the ligands which are able to inhibit the basal transcriptional activity of NRs. 
For example, different inverse agonists of hCAR can abolish the basal transcriptional activity to a 
certain extend.  
 
Figure 2. H12 is repositioned in response to the nature of ligand bound (Aagaard et al., 2011). 
(A) In the presence of inverse agonist/antagonist, the position of H12 allows the binding of co-
repressors through IDs. (B) Binding of agonist switches the H12 into a position that favors the 
binding of co-activators.  
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Structural studies suggested that the active state of the NRs is controlled by the C-terminus of 
LBD (Aagaard et al., 2011; Germain et al., 2006) (Fig 2). The binding of ligands into the LBP 
would cause structural changes in the NRs and induce a series of intracellular interactions. 
Among these changes, the movement of H12 is most evident. When agonist bind into the LBP, 
H12 tends to fold against the LBD and cover the entrance of the LBP. This change facilitates the 
recruitment of co-activators and the activation of transcription. In contrast, if the bound ligand is 
an antagonist or inverse agonist, H12 helix tends to extend away from the core of LBD. 
Resultantly, co-repressor complexes are recruited by NRs and thus inactivate the transcription. 
Hence, the position of AF-2 relative to the rest of the LBD is critical for the selection of co-
regulators: the active position of H12 favors co-activators recruitment and its inactivate position 
facilitates co-repressors recruitment (Nagy and Schwabe, 2004; Privalsky, 2004; Bourguet et al., 
2000). 
 
Here raises another question: how does the position of H12 enhance of impair the selective 
binding of co-activators and co-repressors? Seeing from the interface between the short peptide 
which contained NR box of co-activator and LBD of nuclear receptor, the peptide is held in place 
via hydrophobic interaction and forms two hydrogen bonds between the peptide backbone atoms 
and two conserved residues from LBDs (lysine from H3 and glutamate from H12). Because the 
hydrogen binding requires reasonably close distance and favored orientation between the H12 
and co-activator peptide, the active position of H12 induced by agonists is thus considered as 
important for co-activator recruitment. On the other hand, the X-ray crystal structures suggest 
that the peptide from IDs of co-repressor extends into the regions which are occupied by active 
H12 (Xu et al., 2002). Only in the case of inactive H12, NRs favor the interaction with co-
repressors. Different from the binding of co-activators, the binding of co-repressors does not rely 
on conserved hydrogen bonds, but mainly hydrophobic interactions.  
 
A general co-regulator exchange model has been proposed based on current understanding of the 
regulatory function of co-activators, co-repressors, as well as mediator (Glass and Rosenfeld., 
2000). The transcription, as mentioned above, is a sequential process that happens in a specific 
order, this process may be divided into 5 stages. First, the unliganded or antagonist bound nuclear 
receptor attaches to specific DNA sequences, and recruits co-repressor complex. HDACs, as one 
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component of the co-repressor complex, are used to condense the chromatin structure and repress 
the transcription. Second, upon the binding of agonist, AF-2 of nuclear receptor is activated and 
facilitates the exchange of the co-repressor complex for the co-activator complex, which most 
probably contains the histone modifying factors, such as HATs. Third, HATs or other enzymes 
produce an open chromatin structure via histone modifications. In this step, the other chromatin 
remodelers may also be involved. Forth, exchange the co-activator complex for mediator 
complex and recruit RNA polymerase II. Fifth, mediator complex initiate and activate the gene 
transcription. Based on this model, close cooperation of multiple co-regulator complexes is 
indispensable for the regulation of gene transcription.  
 
1.5 Nuclear receptor specificity of co-regulator peptides 
 
1.5.1  Nuclear receptor specificity of the NR boxes of co-activators 
 
There are a number of co-regulators that share the conserved NR boxes. These co-regulators 
include co-activators (such as SRCs, PGC-1, CBP/p300 and TRBP), co-repressors (RIP140, 
LCoR) and mediator/TRAP. Despite these NR boxes are shared by above-mentioned co-
regulators and most of these NR boxes are able to bind to the receptor directly, they are probably 
not functionally equivalent (Chang et al., 1999). Many findings support the idea that the nuclear 
receptor binding selectivity can be achieved by altering sequences flanking the LXXLL core 
motif (Savkur and Burris., 2004; Chang et al., 1999; McInerney et al., 1998). This may explain 
why NRs usually interact with specific co-regulators. For instance, PPARᵞ has greater affinity for 
CBP than for SRC-1, whereas ERα binds SRC-1 better than CBP (Zhou et al., 1998). 
Interestingly, Wärnmark et al (2010) has reported that the NR boxes of TRAP are differentially 
recruited by ERα and ERβ. These preferences have been utilized to discriminate between NRs 
and even nuclear receptor subtypes either in ligand dependent or independent manner (Bramlett 
et al., 2001; Mclnerney et al., 1998; Darimont et al., 1998). 
 
Single (such as PGC) or multiple copies (such as SRCs) of NR boxes are present in a single co-
activator. In case of multiple copies, the NR boxes are usually differentially utilized by different 
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NRs. For example, SRC-1 contains three NR boxes (NR1, NR2 and NR3), NR2 is sufficient for 
the activation by of ER, whereas TR and RAR require both NR2 and NR3 with correct spacing 
between them. PPARγ and PR need both NR1 and NR2, and again require for correct spacing 
between these two NR boxes (Mclnerney et al., 1998). Biochemical experiments have 
demonstrated that single fragment of SRC-1 containing two or three NR boxes can interact with 
both hetero- and homo-dimers, with one NR box associated with each monomer (Nolte et al., 
1998; Westin et al., 1998; Gee et al., 1999). This observation suggests that co-regulators 
containing multiple NR boxes would probably achieve enhanced binding with NR compared to 
those containing single NR box (Savkur and Burris., 2004).  
 
Murine CAR (mCAR) is proved to interact with co-activators, such as SRCs, ASC-2 and PBP. Of 
these co-activators, SRC-3 interacts with mCAR through S/T and HAT domains, whereas SRC-1 
and SRC-2 interact with mCAR by NR2 (Chen et al., 2011). However, hCAR only shares limited 
sequence and functional similarity with murine CAR. Thus the hCAR activation mechanism by 
the recruitment of SRCs might be different from mCAR.  
 
1.5.2   Nuclear receptor specificity of the NR boxes of mediator  
 
Similar to NR boxes in co-activators, the two NR boxes of a mediator subunit MED1 also display 
preferential binding with certain NRs. For example, steroid hormone receptors, such as ER, show 
preferred binding to the NR1of TRAP, whereas non-steroid hormone receptors, such as TRα and 
VDR, show preferred binding to NR2 of TRAP. However, these two motifs are both required for 
efficient NR-mediated transcription (Chen and Roeder., 2011).  
 
Mediator, as discussed above, functions as recruiter of complexes that interact with the basal 
transcription machinery. Learning from the co-regulator exchange model, the mediator complex 
is most probably involved in many gene transcription. Considering the fact that the NR boxes of 
the mediator are able to directly interact with several NRs, one may assume that hCAR may 
entitle to the similar interaction with mediator. More research work is needed to validate this idea.  
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1.5.3    Nuclear receptor specificity of IDs of co-repressors 
 
Co-repressors SMRT and NCoR interact with NRs utilizing the conserved LXXXI/LXXXI/L 
motif (termed as IDs). SMRT contains two IDs, whereas NCoR contains three (one of which is 
removed by mRNA splicing in one of the isoforms) (Privalsky., 2004; Nagy et al., 1999). It has 
been reported that different NRs exhibit different affinities for these IDs (Privalsky., 2004). For 
instance, RARs preferentially interact with ID2 of SMRT, RXRs can interact with both ID1 in 
SMRT and ID1 in NCoR, T3Rs interact with ID2 and ID3 of NCoR and ID1 and ID2 of SMRT. 
These preferences may be caused by sequence variations in the motif itself or other factors, such 
as sterical influences within co-repressor complex (Perissi et al., 1999). Moreover, the mutation 
within the adjoining sequences from different motifs is also reported to disrupt the interaction 
between NRs and co-repressors. Thus these sequences may also be of great importance for the 
recognition and selection of NRs (Webb et al., 2000). 
 
1.6 Aim of study 
 
This study aimed at investigating the important nuclear receptor interaction motifs of co-
regulators that contribute to hCAR specificity. There are usually multiple interaction motifs 
within each co-regulator. Each of these motifs may underlie critical functions in the activation 
and repression of hCAR transcriptional activity.  
 
In this study, co-activator SRC-1, co-repressor NCoR and TRAP were chosen to represent 
different classes of co-regulators of hCAR. The goal was to clarify the differential recruitment of 
interaction domains of NCoR, SRC-1 and TRAP by hCAR through inspecting the structural 
changes of NR-ligand-co-regulator complexes during MD simulations. Furthermore, this study 
was hoped to provide hints for mutagenesis studies in delineating the critical molecular 
determinants of the interaction between the co-regulator interaction domains of NCoR, SRC-1 
and TRAP. In addition, the ligand specificity of these interactions was hoped to be elucidated.  
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2 Methods and materials 
 
2.1 Model building 
 
The model was based on three essential components: hCAR-LBD, ligand and a peptide segment 
from co-regulator. The ligand-protein complexes were already available for this work and the 
docking of ligands has been described in the publication by Jyrkkärinne et al (2012). A number 
of ligands, which covered a wide range of chemical groups, were selected for this study 
(Jyrkkärinne et al., 2012; Küblbeck et al., 2011a; Küblbeck et al., 2011b; Jyrkkärinne et al., 2008; 
Küblbeck et al., 2008; Li et al., 2008; Huang et al., 2004; Maglich et al., 2003) (Table 1, 
Appendix I). Seven of them are agonists (CITCO, FL81, FL82, permetrin, CLOTR, TPP and 
artemisin) and eight of them are inverse agonists (EE2, androstanol, ANDR, PK11195, S07662, 
clomifene, celecoxib and meclizine). Each studied peptide was placed onto the co-regulator 
groove of liganded or apo hCAR-LBD.  MD simulations of 10 ns were performed for these NR-
ligand-co-regulator complexes. 
 
Three well known co-regulators were chosen for this study. They are co-activator SRC-1, co-
repressor NCoR and TRAP. Short peptide segments were extracted from the interaction domains 
of these three co-regulators. Previous studies proved that these peptides are sufficient to mediate 
the gene expression with the help of NRs (Nagy et al., 1999; Hu and Lazar., 1999). These 
peptides contain ID1 (contains both ID1a and ID1b according to different sequence alignments) 
and ID2 from NCoR, NR1, NR2 and NR3 (NR 1-3 for short) from SRC-1, and NR1and NR2 
(NR1-2 for short) from TRAP. Of these peptides, NR2 of SRC-1 is the only one which has been 
co-crystallized with hCAR-LBD (Xu et al., 2004). The other peptides were built using homology 
modeling and are described below. 
 
2.2 Homology modeling 
 
Prior to homology modeling, the sequence alignments of these co-regulator peptides were studied. 
Many literatures have reported alignments with respect to the first conserved leucine or 
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isoleucine residue within the conserved nuclear receptor interaction domains of co-regulators 
(Plevin et al., 2005; Savkur and Burris., 2004; Bramlett et al., 2001; Wärnmark et al., 2001; 
Heery et al., 2001; Webb et al., 2000; Hu and Lazar., 1999; Perssi et al., 1999; Nolte et al., 1998;  
 
Table 1. Ligands incorporated in MD simulation systems, with their molecular weight (MW) and 
in vitro activities. 
Ligand
a
 Molecular formula 
Molecular 
Weight (MW) 
in vitro activity 
Act
b
 NCoR act
c
 SRC-1act
c
 
CITCO* C19H12Cl3N3OS 436.74 17.6 ± 2.5 2.2 ± 0.4 206.7 ± 9.2 
FL82* C16H15NO 237.30 14.2 ± 2.3 1.0 ± 0.3 81.7  ± 12.7 
FL81* C18H19NO3 297.35 9.7 ± 4.5 1.5 ± 0.1 160.5 ± 12.1 
Permethrin* C21H20Cl2O3 391.29 9.2 ± 2.3 2.7 ± 0.3 113.0  ±17.4 
CLOTR* C22H17ClN2 344.84 6.2 ± 1.5 4.9 ± 0.3 50.8  ± 1.9 
TPP* C18H15O4P 326.28 3.5 ± 0.5 2.7 ± 0.3 123.0  ±15.8 
Artemisin* C15H18O4 262.30 2.1 ± 0.7 2.6 ± 0.6 56.3  ± 17.3 
EE2** C20H24O2 296.40 0.1 ± < 0.1 1.5 ± 0.1 3.4  ±  0.3 
Androstanol** C19H32O 276.46 0.5 ± < 0.1 19.1 ± 1.0 7.1 ± 0.4 
ANDR** C19H30O 274.44 0.2 ± < 0.1 9.7 ± 1.2 10.0  ± 1.1 
PK11195** C21H21ClN2O 352.86 0.6 ± 0.1 23.8 ± 3.7 20.4 ± 4.2 
S07662** C16H16N2O2S 300.38 0.4 ± 0.1 20.9 ± 10.2 1.9  ± 0.5 
Clomifene** C26H28ClNO 405.96 0.4 ± < 0.1 0.6 ± < 0.1 0.7  ± < 0.1 
Celecoxib** C17H14F3N3O2S 381.37 0.6 ± 0.1 0.7 ± 0.1 0.9 ± < 0.1 
Meclizine** C25H27ClN2 390.95 1.6 ± 0.8 0.9 ± 0.1 0.8 ± 0.2 
a
agonist*, inverse agonist** 
b,c
Jyrkkärinne et al., 2012 
b
Activity at 10 µM concentration (for CITCO 1µm) in reporter gene 
assays in mammalian cells, expressed as relative to solvent control ± s.d. 
c
 NCoR and SRC-1 
recruitment was measured at 10 µM concentration (for CITCO 1 µM, and for steroids, EE2, 
androstenol and androstanol at 30 µM) in mammalian two-hybrid assays (M2H), expressed as 
relative to solvent control ± s.d. 
 
McInerney et al., 1998). Such alignments, as shown in Figure 3, are well recognized and were  
used for this study. Based on the sequence alignments,  the homology models of ID1 and ID2 of 
NCoR peptides were build on the basis of the crystal structure of a short SMRT peptide 
21 
 
containing the core residues of ID2 (PDB entry number 1kkq, Xu et al., 2002). Two homology 
models of NCoR ID1 were built, each corresponding to an alternative alignment. The homology 
models of NR1and NR3 of SRC-1, together with NR1-2 of TRAP were built using NR2 of SRC-
1 as template (PDB entry number 1xvp).  
 
The homology modeling was performed using Biopolymer module of SYBYL-X 1.2 (Tripos, St. 
Louis, MO, USA). In order to test the stability of the built co-regulator peptides, these peptides 
were minimized by using 1000 steps steepest descents under the condition of AMBER7-FF99 
force field and Gasteiger-Hückel point charges. The backbones of the peptides only changed 
subtly during minimization. However, in order to have more comparable starting conformations 
of different peptides in MD simulations, these peptides were included into the protein complexes 
as the original states, which were not minimized. The unfavorable interactions that were caused 
by homology modeling were removed or minimized in the following minimization procedures. 
A 
SMRT ID2  NMGLEAIIRKALMGKYDQW 
NCoR ID2      NLGLEDIIRKALMGSFDDK 
NCoR ID1a     LITLADHICQIITQDFARN 
NCoR ID1b ADHICQIITQDFARNQVSS 
 
B 
SRC-1 NR2  ERHKILHRLLQE 
SRC-1 NR1      QTSHKLVQLLTT 
SRC-1 NR3      KDHQLLRYLLDK 
TRAP NR1       SQNPILTSLLQI 
TRAP NR2       KNHPMLMNLLKD 
 
Figure 3. (A) Sequence alignment of human co-repressor SMRT and NCoR interaction domains. 
NCoR ID1a (amino acids 2,048-2,066) and NCoR ID1b (amino acids 2,052-2,070) represent two 
different alignments of NCoR ID1when aligned with SMRT ID2 (amino acids 2,347-2,365). The 
alignment of NCoR ID1a emphasizes the long motif LXXXIXXXI/L, while the alignment of NCoR 
ID1b emphasizes the short motif I/LXXII motif. The alignment of NCoR ID2 (2,261-2,279) is 
based on both motifs. (B) Sequence alignment of human co-activator SRC-1 (NR1: amino acids 
628-639; NR2: amino acids 685 -696; NR3: amino acids 744-755) and human mediator TRAP 
(NR1: amino acids: 599-610; NR2: amino acids 640-651). This is based on LXXLL motif, which 
is also termed as NR box. The most important and conserved residues are highlight in grey. 
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2.3 Incorporation of the co-regulator peptides 
 
Three homology models of two NCoR IDs were built: NCoR ID1a, ID1b and ID2. NCoR 
peptides used the same coordination as SMRT and merged onto the co-regulator grooves of 
hCAR-LBD. This procedure was described in Jyrkkärinne et al, (2012). Peptide SRC-1 NR2 was 
co-crystallized with hCAR-LBD (1xvp). Hence, the coordination of peptide SRC-1 NR2 from 
crystal structure (PDB no. 1xvp) was used for the other homology models, which include 
peptides SRC-1 NR1-2, TRAP NR1-2.  
 
2.4 Set up of the molecular dynamics simulation systems 
 
MD simulations of 10 ns were run for 9 systems (Table 2). Among these MD simulation systems, 
system I only contains apo and liganded hCAR-LBD, while systems II-IX also contain the co-
regulator peptide. Moreover, each system contains 16 subsystems, 15 of them containing ligands 
and one containing apo-structure (ligand-free structure). 
 
For each subsystem, the hydrogen atoms were first added to protein complexes by using tleap 
module of AMBER10 (Case et al., 2008). The protein complexes, as well as the structural crystal 
water molecules were then solvated in a periodic water box, also with tleap. Force field 
parameters and partial charges from ff99sb force filed were used for protein (Hornak et al., 2006). 
For the ligand, the general atomic force field (GAFF) parameter assignments were made by using 
the antechamber module of AMBER10 (Wang et al., 2004), and the atom-centered partial 
charges were generated by using AM1-BCC method (Jakalian et al., 2000). The explicit TIP3 
waters were used for solvation. No salt ions were included in the MD studies. 
 
2.5 Energy minimization  
 
Because peptides were docked onto the co-regulator groove by using the same coordination as 
SMRT ID2 or SRC-1 NR2 peptides, many unfavorable sterical contacts were produced. Thus 
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prior to MD simulations, the protein complexes were minimized by using sander module of 
AMBER10. Note that the docking poses of ligands in the LBP were carefully evaluated 
beforehand and were not considered as the focus of these minimization procedures. 
 
Table 2. Settings and parameters of MD simulation systems 
System
a
 Components of MD systems
b
 MD parametheres 
I No peptide
c
 
hCAR-LBD+ ligand
a
 
Force filed for ligand: GAFF 
Force field for protein: Amber ff99SB 
Box-size: periodic water box 
Simulation time: 10 ns 
Water type: TIP3P 
Ions: none 
Environment: Amber 10 
Cluster: CSC, Finland 
II NCoR ID2 
III NCoR ID1a 
IV NCoR ID1b 
V SRC-1 NR1 
VI SRC-1 NR2 
VII SRC-1 NR3 
VIII TRAP NR1 
IX TRAP NR2 
a
Each system contains 1 apo structure and 15 liganded structures.   
b
The x-ray crystal structure of hCAR ligand binding domain is chain D of PDB entry 1xvp. Of the 
peptides studied here, only for SRC-1 NR2 there was crystallographic data available (1xvp). 
Based on the sequence alignment as shown in Figure 3, the other co-activator peptides were 
generated by homology modeling by using SRC-1 NR2 (1xvp) as template. The co-repressor 
peptides, on the other hand, were also generated by homology modeling, but by using SMRT ID2 
(1kkq) as template. SYBYL was used for the set up of homology models. 
C
System I contains no peptide, is regarded as the comparison group. 
 
The minimization contained two steps. First, the water molecules and the hydrogen atoms of the 
protein complex were minimized by steepest decent with heavy atoms constrain at the strength of 
50 kcal/mol. Second, the protein complex was further minimized by calculating 1000 steps 
steepest decent and 4000 steps conjugate gradients, but using 50 kcal/mol constraints for heavy 
atoms excluding the co-regulator peptide and the last four residues of H12. After these two 
minimization steps, the protein complex was believed to be a good starting point for MD 
simulations. 
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2.6 Molecular dynamics simulations 
 
All MD simulation systems were equilibrated by using sander module of AMBER10 (Weiser et 
al., 1999). The solvent box in each subsystem was heated to 300 K over 7.5 ps and equilibrated 
for 50 ps under the condition of 300 K constant temperature and 1 atm constant pressure, using 
50 kcal/mol constraints for protein heavy atoms. However, the constraints were removed in the 
following procedures.  Subsequently, the MD systems were minimized for 500 steps steepest 
descent and 500 steps conjugate gradients. Then the systems were again heated to 300 K within 
7.5 ps, and equilibrated for 300 ps by using time step of 1.5 fs.  
 
The production dynamic runs of 10 ns were calculated by pmemd module of AMBER10. The 
cutoff value for lennard-Jones interaction was set to 8 Å. And the electrostatic interactions were 
calculated by the particle mesh Ewald (PME) method (Darden et al., 1993). During the MD 
simulations, the shake algorithm was used to constrain the bonds involving hydrogen atoms to 
their equilibrium values (Ryckaert et al., 1977).  
 
2.7 Analysis of trajectories and final structures 
 
The trajectories from MD runs were analyzed for root mean square deviation (RMSD), the 
atomic positional fluctuation (APF) and the protein secondary structure with the ptraj module of 
Amber tools 1.3 (Case et al., 2005). RMSD has been commonly used for evaluating the stability 
of globular protein conformation (Maiorov and Crippen., 1994). It measures the average distance 
between the atoms of two superimposed proteins. In order to check the structural stability during 
MD simulations, the three-dimensional structure of  protein complex during MD simulations and 
the reference protein were superimposed and calculated for RMSD values. The reference protein 
was the first structure after saving coordinates at tleap module. Different from RMSD, APF 
represents the movements of a single residue before and after MD simulations. APF values often 
revealed the most flexible residues, which may provide insights to the functionally important 
structure elements. The stability of protein secondary structures (such as  α-helix, β sheets, etc) 
was also checked.   
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The final structures from 10ns MD runs were generated using ambpdb module of AMBER10. 
These structures were visually examined within the assistance of SYBYL software. In addition, 
all figures in this study were prepared by using SYBYL. The Connolly surfaces of the LBP were 
calculated by MOLCAD module in SYBYL by using 1.6 Å probe radius. 
 
2.8 MM-PBSA binding free energy calculation 
 
In addition to trajectory analysis, MM-PBSA ligand-protein interaction energy (Eprotein-ligand) were 
calculated by standard MM-PBSA method (Hou et al., 2011; Rastelli et al., 2010, Wang et al., 
2001). The calculation was based on 50 snapshots from first nanosecond and another 50 
snapshots from the ninth nanosecond of MD simulations. The output energy values were the 
average free energy of the 50 extracted structures at 1 ns and 9 ns, respectively.  
 
For each snapshot, the ligand-protein interaction energy (Gbind = Gcomplex-Gprotein-Gligand) was 
calculated. The absolute energy values of each structure, such as protein and ligands, can be 
approximately calculated by the sum of molecular mechanical gas-phase energies (EMM), 
solvation free energies (Gsolvation) and entropy contributions (T∆S) (G = EMM +Gsolvation - T∆S, 
where Gsolvation = GGB+Gnp ). EMM was calculated by using the sander program of AMBER10 with 
all protein pairwise interactions included and dielectric constant (ε) of 1.  Gsolvation was calculated 
in the sum of generalized Born equation (GGB) (Onufriev et al., 2000), and non-polar solvation 
energy which related to solvent-accessible surface areas (Weiser et al., 1999). However, 
considering the entropy term ((T∆S) is currently very time-consuming and expensive to run 
(Kongsted et al., 2009; Weis et al., 2006); it was omitted from this calculation.   
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3 Results and discussion 
 
3.1 Structural stability of molecular dynamics simulation systems 
Within the time range of MD simulations, the structural stability of protein complexes was 
evaluated by root mean square deviation (RMSD, Appendix II). Increase of the RMSD values 
indicates the decrease in the structural stability in MD simulation systems. In this model, the 
RMSD values are approximately 4.5 Å at maximum and 1 Å at minimum (Appendix II).  Such 
variation of RMSD is comparable to other MD studies (e.g. Küblbeck et al., 2011a; Windshügel 
et al., 2005). These values revealed that the overall structure of hCAR-LBD remained stable in 
this model.   
Compared with the data obtained from 9 MD systems, RMSD values calculated for system I 
(Table 2) and systems V-IX (Table 2) are around 2 Å in average. On the other hand, the RMSD 
values of systems II-IV (Table 2) are clearly higher, but no greater than 4.5 Å. These above 
results suggested that the repressive activity of NCoR peptides may be responsible for the 
relatively high RMSD values in systems II-IV. This may be because the crystal structure of 
hCAR-LBD that was extracted from CITCO bound hCAR complex is in active state before MD 
simulation. Therefore, by the interaction of NCoR and hCAR-LBD, the transcriptional active 
conformation of hCAR can potentially be transformed into less active states. On the other hand, 
the effect of introducing the co-activator SRC-1 and TRAP peptide would cause fewer changes in 
such systems. The RMSD values in systems V-IX thus could be relatively lower than systems II-
IV. In this context, the original conformation of hCAR at the starting point of MD simulations 
could critically affect the structural responses of hCAR-LBD complex to the co-regulator 
peptides. 
The system stability was further tested by atomic positional fluctuation, APF (Appendix III). It 
represents the backbone fluctuation of single residue in the time range of MD simulations. Over 9 
simulation systems, helices of hCAR-LBD revealed subtle movements with APF values less than 
1 Å. This might be due to the compact architecture of the three-layered helix sandwich, which 
prevents these residues to move freely. On the other hand, the loops (aa. 143-154 and aa. 298-307) 
and β-sheets (aa. 210-225) of hCAR-LBD revealed clearly higher flexibility with APF values in 
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the range of 1 - 4.5 Å. These values are in consistent with previous studies (Küblbeck et al., 
2011a). Consequentially, in this respect, these systems are sufficiently stable to simulate the 
structural changes for further analyzing. 
 
3.2 Molecular dynamics simulations of systems II-IV 
 
3.2.1  Structural changes of hCAR-LBD induced by interaction with 
IDs of NCoR 
 
The C-terminal residues of hCAR-LBD are essential in stabilizing the position of H12. As 
suggested by APF values, these residues moved more in systems II-IV compared to system I 
(Appendix IV, Fig 1 – Fig 4). Thus, by interacting with NCoR peptides, the C-terminus of 
hCAR-LBD was destabilized. Such destabilization may change the activity of hCAR-LBD. 
By including ID2 peptide of NCoR into system II, inverse agonists tended to perturb the helical 
content (HC %, means the percentage of MD simulation time for the residues to stay in helical 
conformation) of H12 (Appendix V, Fig 2B), and shifted H12 out of the active position (Fig 4B). 
Strong inverse agonists, such as S07662 and PK11195, appeared to move H12 toward H10 (Fig 
4B), with HC % of H12 decreased to minimum 35% and 13%, respectively (Appendix V,  Fig 
2B). Interestingly, inverse agonists androstanol and clomifene were seen to dramatically 
decreased HC % of H12 to less than 8% (Appendix V, Fig 2B), and re-orientated H12 to the 
direction of HX (Fig 4B). Other inverse agonists (ANDR, celecoxib, meclizine and EE2) that 
stabilized the C-terminal residues (Appendix V, Fig 2B), only induced minor structural changes 
(Fig 4B). With regards to agonists, permethrin, CLOTR and artemisin, acted more like inverse 
agonists, which also destabilize the C-terminal residues (Appendix V, Fig 2A) and move H12 to 
H10. However, CITCO and FL81, as strong agonists, tended to maintain H12 in a highly stable 
active state (Fig 4A).  
System III included ID1a peptide of NCoR. Within this MD simulation system, 2 out of 8 inverse 
agonists (PK11195 and androstanol) tended to destabilize the C-terminal residues of hCAR-LBD  
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Figure 4. Positions of H12 in the final structures of the 10 ns MD simulations. (A) agonists and 
(B) inverse agonists in system II; (C) agonists and (D) inverse agonists in system III; (E) agonists 
and (F) inverse agonists in system IV. Apo (transparent, blue) is shown as a reference with each 
liganded structure (cyan).   
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and shift H12 to the direction of HX and H10 (Fig 4D). Particularly, PK11195 was seen to 
decrease HC % of H12 to under 10%, while androstanol decreased the value to 22% at minimum 
(Appendix V, Fig 3B). Despite S07662 having a better inverse agonist profile, it maintained H12 
in the active position (Fig 4D). H12 in the presence of other inverse agonists either moved to the 
opposite direction of H10 (ANDR), or remained in the active position as what was seen in 
S07662. On the other hand, agonists FL81, FL82 and CLOTR appeared to stabilize H12 in the 
active position, while agonist CITCO was seen to greatly deform HX and H12 (Fig 4C). From 
above, the positions of H12 in the presence of S07662 and CITCO suggested disagreements with 
the in vitro test of ligand-dependent hCAR activity (Table 1). 
The second homology model of ID1 motif of NCoR, namely ID1b was included in system IV. 
Intriguingly, the active position of H12 was maintained by 5 out of 7 agonists (CITCO, 
permethrin, FL81, CLOTR and FL82) and 3 out of 8 inverse agonists (ANDR, S07662 and 
androstanol) (Fig 4E and 4F). In the case of other inverse agonists (PK11195, EE2, celecoxib, 
meclizine and clomifene), H12 remained as in apo-structure (Fig 4F). Based on above findings, 
ID1b peptide was not able to induce conformational changes towards inactive state of hCAR-
LBD.  
 
3.2.2  Binding of NCoR IDs onto hCAR co-regulator groove 
 
The NCoR co-regulator groove is constituted by residues mainly from H3, H4 of hCAR-LBD 
(Appendix VI, Fig 1). Any movements of the residues that lie in the groove would influence the 
property of the groove and even the binding of upcoming co-regulators. Such movements were 
seen in systems II-IV and it caused the dissimilar binding mode of three NCoR peptides. For 
instance, in apo-structure of systems II-III, H12 adopted active conformation, which prevented 
efficacious binding of NCoR peptides by introducing sterical hindrances (Appendix VI, Fig 1A 
and 1B). In apo-structure of system IV, H12 was observed to shift toward H10, and as a result, 
the peptide was allowed to extend further into the groove and probably achieved enhanced 
binding. However, the 3-turn helical conformation of ID1a and ID1b (Appendix VI, Fig 1B and 
1C) were greatly disturbed.   
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Figure 5. The NCoR ID2 peptide on hCAR-LBD. (A) represents the co-regulator groove in the 
presence of CITCO, and (B) represents the co-regulator groove in the presence of S07662. The 
core residues L1, I5 and L9 of NCoR ID2 on the liganded structures (cyan) are compared to the 
apo-structure (blue). The molecular surface of hCAR-LBD is shown in grey.The black circule 
highlight that S07662 liganded structure achieved imporved binding of NCoR ID2.   
 
The complementary binding of the three core residues (depicted in Appendix VI) into the groove 
may serve as an indication of strong interaction between hCAR and co-regulator peptides. The 
binding of ID2 peptide of NCoR onto the groove of CITCO and S07662 liganded structures are 
pictured in Figure 5. The positions of three core residues of peptide ID2 (L1, I5, L9) are also 
shown. Based on the above assumption, the S07662 liganded structure achieved improved 
binding of NCoR ID2 peptide. Different from what was seen in apo-structure, the peptide bound 
to the bottom of the groove of S07662 liganded structure, and the three core residues intensively 
interacted with the hydroponic groove (Fig 5B). However, in the presence of CITCO, the core 
residue L1 of ID2 peptide pointed outwards the groove (Fig 5). Hence the binding of ID2 peptide 
was probably weakened by CITCO.  
The conformation of ID2 peptide of NCoR, as well as the positions of three core residues in the 
presence of other ligands is shown in Figure 6. Under the influence of inverse agonist, such as 
PK11195, androstanol and clomifene, the peptide appeared to bind deeply into the groove. This is 
in line with the inactive positions of H12 in the corresponding structures (Fig 4B). Celecoxib, 
meclizine, EE2, as suggested by the H12 movements, either enhanced  
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Figure 6. The core residues L1, I5 and L9 of NCoR ID2 on the liganded structures (cyan), 
compared to the apo-structure (blue).  
 
the binding of NCoR ID2 to a small extent (meclizine) or highly resembled the binding of peptide 
in apo-structure (EE2 and celecoxib). The binding of peptide under the effect of agonists also 
differed from one to another. Permethrin, TPP, artemisin that shifted H12 to H10, indicated better 
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binding of the peptide. This can be explained by their weak or modest NCoR binding affinity: 
permethrin, TPP and artemisin that each increased 2.7, 2.7 and 2.6 fold of NCoR recruitment 
compared to apo in M2H assays (Table 1). CLOTR, which yielded 4.9 fold increases in NCoR 
recruitment, were also found to enhance the binding of the peptide. CITCO, FL81, and FL82, as 
potent agonists, maintained the active state of H12 and in the meantime, disfavored the binding 
of the co-repressor peptide ID2.  
Notably, the N-terminal residues of the peptide ID2 of NCoR tended to move toward the bottom 
site of the groove in order to enhance the interaction between L1 and the groove, especially in the 
presence of inverse agonist. However, ANDR was the only exception compared to other inverse 
agonists. Since the ANDR liganded complex induced a clear shift of L1 to the opposite side of 
the peptide and hCAR interacting interface, the interaction between hCAR and the peptide ID2 
might be weakened or disfavored. 
The interaction between peptide ID1a of NCoR and hCAR-LBD groove was enhanced by 
PK11195 and androstanol (Appendix VII, Fig 1). However, other inverse agonists, including 
S07662, failed to do so. The homology model of ID1b, on the other hand, failed to bind to the 
groove in any liganded structures (Appendix VII, Fig 2). Compared to peptide ID2, it seems that 
the homology models of ID1a and ID1b acted in a very different way. Moreover, due to the fact 
that even strong inverse agonists conferred to active state in the presence of ID1a and ID1b, the 
structural changes in system III and IV are inconsistent with the experimental data (Table 1). In 
addition, the role of ligands in ID1 interaction remained unclear. 
 
3.2.3  Differences between ID1 and ID2 motifs of co-repressor NCoR 
 
Various degrees of peptide helical content perturbation was seen in the three NCoR simulation 
systems (II-IV). In system II, the 3-turn helical conformation of peptide ID2 was successfully 
maintained in 13 out of 15 liganded structures (Appendix VIII, Fig 1A). However, most of the 
liganded structures induced by peptide ID1a and peptide ID1b failed to keep such conformation 
(Appendix VIII, Fig 1B and 1C). Learning from previous studies on molecular determinants of 
NR-co-repressor interaction, and referring to the crystal structures of NCoR ID1 and SMRT IDs, 
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the 3-turn helical conformation is regarded as important for the repressive activity of NCoR and 
SMRT (Phelan et al., 2010; Xu et al., 2002; Perissi et al., 1999). Thus, the movements of H12 of 
hCAR-LBD (as described in section 3.2.1) and the peptide binding behavior onto the co-regulator 
groove (as described in section 3.2.2), and the high stability of 3-turn helical conformation of 
NCoR ID2 peptide revealed that ID2 is probably the interaction motifs that specifically interact 
with hCAR.  Conversely, the peptides of ID1a and ID1b with disturbed helical conformation 
during the MD simulations, combing the structural changes of H12 and peptide binding in system 
III and system IV, may suggest weakened peptide interaction to the hCAR groove.  
In fact, the arguments on whether ID1 and ID2 of NCoR utilize the same or the distinct 
mechanism to interact with NRs yet have no answer (Phelan et al., 2010). However, ID1 and ID2 
act distinctively in this model. This may be caused by the inaccurate structures of these two 
motifs, which were generated by homology modeling using ID2 of SMRT as template. Since 
NCoR ID2 shares greater sequence similarity with SMRT ID2 (Fig 3), it is possible that in this 
study ID2 has more accurate peptide conformation than ID1a and ID1b. Yet it is not clear how 
such assumed accuracy (or inaccuracy of NCoR ID1a and ID1b) could influence the modeling 
systems. But it is certain that the sequence alignment for homology modeling has played an 
important role in the model performance. These differences between ID1a and ID1b modeling 
results implied that the core residues or even the flanking residues of the IDs should be 
maintained in certain conformation, in order to achieve strengthened NCoR binding affinity.  
In addition, when comparing the ID2 binding mode of NCoR to that of SMRT (Jyrkkärinne et al., 
2012), the three-turn helical conformations of both NCoR and SMRT peptides are maintained. 
Differently, the core residues of SMRT appeared at the same side and all interact with the co-
regulator groove, whereas in NCoR they do not.  
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3.3 Molecular dynamics simulations of systems V-VII 
 
3.3.1  Structural changes of hCAR-LBD induced by interaction with 
NR boxes of SRC-1 
 
The low RMSD values in systems V-VII suggested that the complexes of hCAR have limited 
movements during MD simulations. APF values (Appendix IV, Fig 5 – Fig 7) suggested the 
stability of C-terminal residues was enhanced by agonists and slightly destabilized by inverse 
agonists. This is in agreement with the nature of ligands: (1) according to previous study 
(Windshügel et al., 2011), agonists are presumably to maintain or precede the active form of 
hCAR. Thus in this model, agonist-bound structure are obligated to fewer movements in C-
terminus; (2) inverse agonists are ligands who potentiate the perturbation of the active form of 
hCAR. Instead of C-terminus stabilization, they intend to destabilize it. 
In system V that included NR1 box of SRC-1, the helical conformation of HX appeared to be 
enhanced by agonists, while decreased by inverse agonists (Appendix V, Fig 5). However, H10 
and H12 were very stable, despite that the bound ligand could be either an agonist or an inverse 
agonist. Importantly, the positions of H12 only changed subtly (Appendix IX, Fig 2). For most 
hCAR complexes, H12 was maintained in the active form (Fig 7). However, there was one 
exception: H12 in androstanol liganded structure moved towards H10. This implies that 
androstanol may inhibit the binding between hCAR and co-activator peptides. From above, there 
are only few differences that can be identified between the behavior of C-terminal residues (esp. 
the positions of H12) in the presence of agonists and inverse agonists. Accordingly, it would be 
difficult to analyze the effect of the ligand binding based on the performance of this MD system. 
The APF values in this system are lower than that of system I. This suggests that the peptide 
containing NR1 box may help to stabilize the active form of hCAR-LBD.  
In system VI, there were no apparent changes in the helical stability of H10 and HX between 
agonists and inverse agonists liganded structures (Appendix V, Fig 6). However, inverse agonists 
such as clomifene, EE2, PK11195 and androstanol were found to slightly decreased the helical 
stability of H12 (Appendix V, Fig 6) and moved H12 out of the active conformation (Fig 7D and 
35 
 
Appendix IX, Fig 3B). This was not seen in the case of any agonists. The inverse agonist induced 
movements of H12 would probably impair the binding of co-activators. Based on above findings, 
one can assume that NR2 box of SRC-1 may be potentially important for the activity of hCAR in 
a ligand specific manner.  
Figure 7. Positions of H12 in the final structures from the 10 ns MD simulations. (A) agonists 
and (B) inverse agonists liganded structures in system V; (C) agonists and (D) inverse agonists 
liganded structures in system VI; (E) agonists and (F) inverse agonists liganded structures in 
system VII. Apo (blue) is shown as a reference with each liganded structure (cyan).  The green 
ribbon in (A) is FL81 and in (B) is androstanol.  
 
In system VII, the co-regulator peptide containing NR3 box of SRC-1 was included into hCAR 
complexes. Artemisin appeared to destabilize the helical content of both H10 and HX, while 
S07662 and meclizine appeared to drive C-terminus of H10 out of the helical conformation 
(Appendix V, Fig 7). In the presence of other ligands, the three helices at c-terminus were highly 
stabilized (Appendix V, Fig 7). The active positions of H12 were maintained and exhibited no 
clear differences from one ligand to another (Appendix IX, Fig 4).  
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3.3.2  Binding of SRC-1 NR boxes onto hCAR co-regulator groove 
 
In systems V-VII, the co-activator groove is formed by H3, H4 and H12 of hCAR-LBD. In the 
apo-structure of these systems, H12 remained in the active position as before MD simulations 
and the peptides from SRC-1 were stabilized in 2-helical conformation with only subtle 
movements (Appendix VI, Fig 2). 
The binding of NR boxes of SRC-1 can be affected by ligand binding. The interaction between 
peptide containing NR1 box of SRC-1 and hCAR-LBD is enhanced by both CITCO and S07662 
compared to apo-structure (Fig 8A and 8B). But in system VI, peptide containing NR2 box 
moved away from the groove of S07662 bound hCAR-LBD complex (Fig 8D). In system VII, 
the binding of CITCO and S07662 had no significant influences on the binding of peptide 
containing NR3 box with the C-terminal residues of the peptide move slightly (Fig 8E and 8F).  
The positions of core residues in co-regulator interaction motifs were evaluated for each liganded 
structure in the presence of NR1-3 boxes (Appendix VII, Fig 3 – Fig 5). Based on the positions of 
co-regulator core residues, the binding in liganded structure were compared to apo. In system V, 
it seemed that both agonists (CITCO, TPP) and inverse agonists (S07662, androstanol, EE2, 
meclizine) were able to strengthen the interaction between peptide containing NR1 box and 
hCAR-LBD (Appendix VII, Fig 3). In system VI, agonists CLOTR and artemisin enhanced the 
binding of peptide containing NR2 box, while agonists TPP, FL82 and inverse agonist S07662 
tended to destabilize the peptide and weaken the binding of peptides (Appendix VII, Fig 4). In 
system VII, 2 agonists (CLOTR, and FL82) and 4 inverse agonists (ANDR, androstanol, 
celecoxib and PK11195) enhanced the binding of NR3 peptide (Appendix VII, Fig 5). Based on 
above observations, the binding of co-activator peptide not only depends on the bound ligand, but 
also rely on the type or the flanking sequences of the peptides themselves.  
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Figure 8. The co-regulator groove of hCAR with peptides from co-activator SRC-1. The left 
column compares the binding of (A) NR1, (C) NR2 and (E) NR3 peptide on CITCO liganded 
structures to apo-structure. The right column compares the binding of (B) NR1, (D) NR2 and (F) 
NR3 peptide on S07662 liganded structures to apo-structure. The molecular surface of hCAR-
LBD is shown in grey. SRC-1 peptides from apo-structure is shown in blue and change into cyan 
in liganded structure. 
 
3.3.3  Differences between NR1, NR2 and NR3 boxes of co-activator 
SRC-1 
 
Based on the theory of ‘mouse-trap’ model of NR ligand binding (Savkur and Burris., 2004) and 
the crystal structures of SRC-1 peptides, the strong interaction between NR boxes and co-
regulator groove relies on the relative position of H12 to NR box (Windshügel et al., 2005). In 
systems V-VII, H12 was maintained in the active position (see section 3.3.1). The peptides 
containing NR boxes were stabilized in 2-turn helical conformation (Appendix V, Fig 5 - Fig 7) 
with few movements compared to apo-structure (Appendix VII, Fig 3 - Fig 5). It seems that the 
three NR boxes all facilitate the interaction of SRC1 peptides with hCAR-LBD.  
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Different from system V and VII, the binding of peptide with hCAR-LBD was significantly 
different between agonist and inverse agonist liganded structures in system VI. First, the active 
position of H12 was maintained by agonists, whereas inverse agonists moved H12 toward H10 
(see section 3.3.1). Second, NR2 peptide in system VI was slightly destabilized (HC% > 74%) by 
many ligands (Appendix VIII, Fig 2B). In particular, K688 and I689 that compose the N-
terminus of NR2 helix were released from helical conformation in 2 out of 7 agonists bound 
structures (FL81 and FL82) and 4 out of 8 inverse bound structures (S07662, ANDR, EE2, 
celecoxib). Since the helical conformations of NR boxes were destabilized, the peptide binding 
affinity would probably be weakened, especially in the presence of inverse agonist.  
On a minor note, CITCO bound structure in the presence of NR3 peptide of SRC-1 yielded 2.5 Å 
RMSD at the time point of 6.8 ns (Appendix II, Fig 7A). This value is one of the greatest 
fluctuations within systems V-VII. Since CITCO obtained less favorable ligand-protein 
interaction energy in system VII (see section 3.8), it is suspected that the fluctuation revealed by 
RMSD values may lead to the changes of ligand-protein interaction energy. 
 
3.4 Molecular dynamics simulations of system VIII-IX 
 
3.4.1  Structural changes of hCAR-LBD induced by interaction with 
NR boxes of TRAP 
 
The RMSD values in systems VIII-IX are within the range of 1 - 2 Å. These values suggest that 
the peptides from TRAP have stabilized the protein complexes during MD simulations. As 
suggested by APF values (Appendix IV, Fig 8 –  Fig 9), a few ligands tended to destabilize the 
C-terminus of hCAR-LBD. These ligands include TPP (APF of residue 337 > 2 Å), CITCO (APF 
of residue 337 > 1.4 Å), clomifene (APF of residue 346 > 1 Å) in system VIII and PK11195 
(APF of residue 337 > 1.9 Å) in system IX. However, based on the low APF values and high HC % 
values (Appendix V, Fig 8 - 9) in the C-terminus of most liganded structures, TRAP peptides 
were regarded as important to stabilize the C-terminus of hCAR. In this regard, the behaviors of 
TRAP peptides resemble the SRC-1 peptides, but differ from NCoR peptides.  
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Figure 9 illustrates the positions of C-terminal residues in both systems (see also Appendix IX, 
Fig 5 – Fig 6). In system VIII, agonists and inverse agonists were able to maintain H12 in active 
position. Differently, ligands in system IX tended to move H12 upwards. Moreover, in system IX, 
inverse agonists tended to shift H12 toward H10 to a small extent, while agonist did not. 
However, since the in vitro data of the recruitment of TRAP peptides into hCAR are not available, 
it is difficult to interpret the consequences on hCAR activity due to movements of H12 and other 
C-terminal residues.  
 
Figure 9. Positions of H12 in the final structures from the 10 ns MD simulations. (A) agonists 
and (B) inverse agonists liganded structures in system VIII; (C) agonists and (D) inverse agonists 
liganded structures in system IX. Apo (blue) is shown as a reference with each liganded structure 
(cyan).   
 
3.4.2  Binding of TRAP NR boxes onto hCAR co-regulator groove 
 
The TRAP peptides bound to the co-regulator groove that formed by residues from H3, H4 and 
H12 of hCAR-LBD (Appendix VI, Fig 3). The two-turn helical conformation of TRAP was 
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maintained in both apo-structures. In comparison to apo, NR1 departed away from the co-
regulator groove in the presence of CITCO (Fig 10A), while S07662 seemed to neither enhance 
nor weaken the binding of NR1 box (Fig 10B). However, peptide containing NR2 in CITCO and 
S07662 liganded structures remained in the same position as apo (Fig 10C and 10D). Based on 
the positions of core residues of peptides, the binding of two NR boxes of TRAP in the presence 
of diverse ligands were analyzed. It has been found that the peptide containing NR1 tended to 
depart away from groove in 11 out of 15 liganded structures (5 agonists: CITCO, permethrin, 
TPP, FL81and artemisin; 6 inverse agonists: ANDR, PK11195, androstanol, celecoxib, meclizine 
and EE2) (Fig 11A and 11B). By contrast, in system IX, the core-residues of NR2 peptide 
remained unchanged compared to that of apo (Fig 11C and 11D). For both systems, there were no 
clear differences in the binding of TRAP between agonists and inverse agonists liganded 
structures.  
 
Figure 10. The co-regulator groove of hCAR with TRAP. The left column compares the binding 
of (A) NR1 and (C) NR2 peptide on CITCO liganded structures to apo-structure. The right 
column compares the binding of (B) NR1 and (D)  NR2 peptide on S07662 liganded structures to 
apo-structure. The molecular surface of hCAR-LBD is shown in grey. SRC-1 peptides from apo-
structure is shown in blue and change into cyan in liganded structure. 
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Figure 11. The core residues L1, L4 and L5 of TRAP NR1 on the (A) agonist and (B) inverse 
agonist liganded structures compared to the apo-structure (blue). The core residues L1, L4 and 
L5 of TRAP NR2 on the (C) agonist and (D) inverse agonist liganded structures compared to the 
apo-structure (blue). 
 
3.4.3   Differences between NR1 and NR2 boxes of mediator TRAP 
 
Based on the analysis regarding systems VIII and IX, several structural features that involved 
NR1 and NR2 of TRAP were evident. First, the active position of H12 was maintained in both 
systems; the helical stability of H12 was enhanced by the two NR boxes in comparison to system 
I. Second, the 2-turn helical conformation of TRAP peptides was maintained in both apo and 
liganded structures (Appendix VIII, Fig 3). Third, NR1 box tended to depart away from hCAR as 
compared to apo, while NR2 peptide tended to maintain in the same position as apo.  
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Because the in vitro activity of TRAP regarding hCAR interaction is currently unavailable, the 
role of NR1 and NR2 in the TRAP-dependent hCAR regulation remains to be solved. Based on 
this study, the distinct binding mode of NR1 and NR2 suggested that NR2 box would probably 
interact with hCAR with higher preference than NR1 box. It has been reported that VDR can 
preferentially recruit NR2 box of TRAP (Rachez et al., 1999), thus this preference might be 
maintained for its close relative, hCAR. 
 
3.5 Changes in the stability of HX 
 
HX is a four-residue helical structure that connects H10 to H12. HX is known for its rigidity and 
potential importance on hCAR constitutive activity (Xu et al., 2004). Nettles et al (2005) further 
suggested that HX plays an important role in the allosteric communication between dimeric 
partners. And on the basis of such communication, the activity of NRs can be finely tuned. 
Moreover, Wright et al (2011) have proved that HX dynamics is critical for the activity of murine 
CAR. This may also hold true for hCAR. In the data of this study, peptides from co-activator 
SRC-1 and mediator TRAP were observed to maintain the high helical content of HX in the 
presence of most ligands (Appendix X). By contrast, the three peptides from NCoR appeared to 
destabilize the helical content of HX, especially in the presence of inverse agonists (Appendix X).  
Helical content stability of HX in all simulation systems was dependent both on ligands and co-
regulator peptides. In the absence of co-regulator peptide, the inverse agonists were likely to 
stabilize HX, while agonists were not (Fig 12). But in the case of the many co-regulator peptides 
(ID2, ID1a and ID1b of NCoR, NR1 box of SRC-1 and NR1-2 boxes of TRAP), HX was 
stabilized by agonists to a greater extent than by inverse agonists. It is noteworthy that in system 
V, which contained NR1 box of SRC-1, the average HC % value of agonists is up to 78.22%, 
which is 87% higher compared to HC % of inverse agonists. However, SRC-1 NR2 and 3 
exhibited no major differences between agonists and inverse agonists bound structures. 
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Figure 12. Helical content (HC %) of the HX helical conformation during MD simulations for 9 
MD systems. The average value of HC % is compared between the agonists and inverse agonists 
liganded structures. Since the in vitro data shows that clomifene, meclizine and celecoxib are not 
able to recruit NCoR, these three ligands were excluded for calculating the average HC % values 
in the ligand structures of inverse agonists.  
 
 
3.6 Changes in the stability of H2-H3 loop 
 
The APF values suggested that the loop connecting H2 to H3 (aa. 143-154) is probably the most 
flexible part of hCAR-LBD (Appendix II). In systems I, III and VIII, the loop appeared to be 
stabilized in apo, but moved more in the presence of ligands, especially inverse agonists 
(Appendix XI, Fig 1, Fig 3 and Fig 8). In contrast, other systems were seen to achieve most 
flexible loop in the absence of ligand (apo). Thus, ligand can help to stabilize or destabilize this 
loop under different context. Moreover, agonists appeared to have few effects on this loop, while 
inverse agonists tended to destabilize it. This was also seen in the modeling studies with SMRT 
and hCAR (Jyrkkärinne et al., 2012).  
The loop changes in apo and four liganded structures in systems II-IX were compared to system I 
(Fig 13). First, in apo-structures, most peptides contributed to the destabilization of this loop with 
the exception of NCoR ID1a in system III and TRAP NR1 in system VIII. Second, upon the 
binding of strong agonists, such as CITCO and permethrin, the loop appeared to be stabilized by 
most co-regulator peptides (Fig 13B and 13C). Third, in case of strong inverse agonists, the 
stability of this loop seemed to be reduced by most co-regulator peptides: 5 out of 8 tested 
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peptides (SRC-1 NR2 and 3, NCoR ID1 and 2b, TRAP NR1) in S07662 (Fig 13D) and 6 out of 8 
(SRC-1 NR1, 2 and 3, NCoR ID1a, TRAP NR1 and 2) in PK11195 (Fig 13E). From above, one 
can assume that the loop changes rely on the binding of co-regulators and the nature of ligand.  
The loop is in a position that has few or no direct interaction with ligand or LBP. However, it 
may serve as one of the ligand entry sites (Jyrkkärinne et al., 2012; Renaud et al., 1995; Martinez 
et al., 2005). The large fluctuation of the loop would probably result in the opening of the LBP. 
For instance, celecoxib, clomifene, meclizine and permethrin in system I, which had large 
fluctuation in H2-H3 loop region, all appeared to have open cavity (Fig 14).  
 
3.7 Changes in the shape and volume of the ligand binding pocket 
 
Ligands bind to the LBP of hCAR mainly through hydrophobic interaction. The pocket is known 
for its elasticity and the ability to accommodate a wide range of ligands. In this study, the LBP 
over 9 simulation systems were checked. Both the ligand and the co-regulator peptides were 
found to induce the changes of either the shape or the volume of the LBP.  
 
In each system, the apo-structure usually had the smallest volume of cavity (Table 3). It seems 
that the cavity starts to expand when the ligand enters inside. Supportively, in system II, 
clomifene has achieved a close cavity (1027 Å
3
), which is 110% larger than the cavity of apo 
(487 Å
3
) and 65% larger than that of FL82 (624 Å
3
). Like other ligands, CITCO also expanded 
the volume of the cavity in most MD systems (systems I-IV and VI-IX). Such as in system VII, 
CITCO achieved a 58% larger cavity than apo (CITCO: 709 Å
3
; apo: 450 Å
3
). However, the LBP 
of CITCO (539 Å
3
) is 10% smaller than the cavity volume of apo (600 Å
3
) in system V. Since 
CITCO has high MW, the shrinkage of the cavity was most likely caused by the enhanced 
interaction between CITCO and the LBP residues. Potentially, this may be related to the strong 
activation potential of SRC-1 NR1 box and the strong agonism of CTICO.  
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Figure 13.  APF values of the backbone atoms of hCAR-LBD during the 10 ns MD simulations. 
H2-H3 loop in (A) apo-structure and in the liganded structures of (B) CITCO, (C) permethrin, 
(D) S07662, and (E) PK11195.  
 
There are in total 14 pockets which opened in the final structures from 10 ns of MD simulations 
(Table 3). They are all from the liganded structures: 5 in system I (permethrin, ANDR, clomifene, 
celecoxib and meclizine), 2 in system II (FL81 and artemisin), 2 in system III (artemisin and 
clomifene), one in system VII (clomifene), 3 in system VIII (FL81, EE2 and meclizine) and one 
in system IX (meclizine). Since the unstable LBP will ultimately affect the stability of the overall 
structure, and destroy the structural basis for the interaction of co-regulators or transcriptional 
machines, the opening of the cavities has most probably great effect on the function of hCAR.  
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Table 3. The volume of the ligand binding pocket in 9 MD simulation systems, the unit for the 
volume is Å
3
. 
Ligand
a
 
System 
I II III IV V VI VII VIII IX 
APO 471 487 388 541 600 413 450 437 441 
CITCO* 609 722 769 716 539 682 709 661 741 
FL82* 599 624 632 557 604 712 575 635 576 
FL81* 652 n.a.
(1)
 702 670 657 625 670 n.a.
(1)
 672 
Permethrin* n.a.
(1)
 896 814 722 795 787 772 787 777 
CLOTR* 657 686 720 793 792 683 791 683 699 
TPP* 716 691 647 674 649 721 767 589 627 
Artemisin* 624 n.a.
(2)
 n.a.
(2)
 528 556 684 589 646 564 
EE2** 710 748 645 631 690 717 704 n.a.
(2)
 716 
Androstanol** 705 626 717 696 736 794 669 733 690 
ANDR** n.a.
(2)
 673 667 766 643 652 716 639 697 
PK11195** 665 699 790 734 685 806 769 764 946 
S07662** 577 709 669 600 651 603 636 636 618 
Clomifene** n.a.
(1)
 1027 n.a.
(2)
 900 831 790 n.a.
(1)
 840 798 
Celecoxib** n.a.
(2)
 721 742 703 677 619 763 844 585 
Meclizine** n.a.
(1)
 777 777 795 679 788 873 n.a.
(1)
 n.a.
(1)
 
a
agonist*, inverse agonist**  
n.a. states the ligand binding pocket is open and the volume is thus not measurable. The number 
in bracket represents the sites where the pocket opens: (1) the H2-H3 loop region; (2) near H12.  
 
In general, there were two sites where the cavity opened: (1) the H2-H3 loop region, such as 
FL81 in system II (Fig 14); (2) with six structures near H12, ANDR and celecoxib in system I, 
artemisin in system II, artemisin and clomifene in system III, and EE2 in system VIII. In case of 
(2), the opening site extended to the surface of hCAR-LBD and therefore probably occupied the 
place for co-regulator binding, thus it is suspected that the interaction between the co-regulator 
peptide and hCAR would be greatly weakened. 
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Figure 14. The opening of the ligand binding pockets of hCAR-LBD after 10 ns MD simulations: 
ANDR, celecoxib, clomifene, meclizine and permethrin liganded structures in system I, and   
FL81 and artemisin liganded structures in system II.  
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3.8 MM-PBSA ligand-protein interaction energy 
 
Protein-ligand interaction energy (Eprotein-ligand) can be used to compare the binding affinities of 
different ligands. Since the co-regulator peptides have impact on the shape of the LBP, as well as 
overall structure, the binding of co-regulator peptides can be regarded as indirectly related to 
these protein-ligand interaction energy values. In practice, the interpretation of these changes can 
be demanding due to several reasons: (1) when calculating the interaction energy, the entropy 
calculation was left out in the convenience of computing time. Thus the calculated values may 
have discrepancy with the real energy values (Kongsted et al., 2009); (2) LBP is highly flexible, 
not all the structural changes of NRs are predictable upon the binding of diverse ligands (Jin and 
Li., 2010). However, the energy values may provide supplementary information for further 
studies. 
 Küblbeck et al (2011a) have reported a good correlation between in vitro activities and protein-
agonist interaction energy from the 1 ns MD simulations which exclude co-regulator peptides. 
However, in this study, there was not that good correlation between the calculated interaction 
energy and experimental data. It is true that the strong agonists correlate to favorable interaction 
energy, such as CITCO, permethrin and FL81(Appendix XII). The less potent agonists, such as 
CLOTR, artemisin and TPP have less favorable interaction energy. The major discrepancy was 
with FL82: though it is a strong agonist, it had less favorable calculated interaction energy. On 
the other hand, within the range of inverse agonists, the interaction energy is not relevant to the 
potency of antagonism, but depends on the co-regulator peptides and other factors, such as 
molecular size. It is possible that the favorable interaction energies of clomifene and meclizine 
are due to their high MW and many hydrophobic interactions with residues from LBP.   
 
For each simulation, E1ns and E9ns values were calculated. E1ns represents the ligand-protein 
binding energy at 1 ns and accordingly, E9ns represents the energy at 9 ns of MD simulations. The 
differences (E1ns-E9ns) can indicate that whether the interaction between ligand and the LBP was 
strengthened (E1ns-E9ns > 0) or weakened (E1ns-E9ns < 0) during the MD simulations. The major 
energy deviations were observed in SRC-1 NR3 complexed structures (Fig 15). For instance, the 
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binding energy of TPP increased by 11 kcal/mol, while with clomifene (-9 kcal/mol) and 
meclizine (-4 kcal/mol) the changes were to the opposite. In addition to SRC-1 NR3, with NCoR 
ID1a and TRAP NR1, there were a few larger changes during the MD simulations; with other 
peptides, the interaction energies did not change much.  
 
 
Figure 15.  Energy differences (E1ns-E9ns) (celecoxib was not calculated due to software 
deficiency) for each ligands in 9 MD systems. When the value is positive (E1ns > E9ns ), the ligand 
binding is suggested to be enhanced during the process of MD simulations. But when the value is 
negative, the ligand binding suggested to become less favorable.   
 
To further validate the role of co-regulator peptides, the energy differences between co-regulator 
peptide-containing systems (II to IX) and system I (the system that contains no peptides and 
services as a reference with each peptide-containing system) were calculated (EI -EII-IX). When 
the value is positive, the co-regulator peptide is proposed to have enhanced the ligand binding, 
and vice versa. As shown in Fig 16, SRC-1 NR-3 and NCoR ID1a are responsible for the major 
changes. In the presence of SRC-1 NR3, great energy bonus was achieved by TPP (10 kcal/mol) 
and CLOTR (6 kcal/mol), but CITCO, clomifene and meclizine dropped down significantly by -
11 kcal/mol, -9 kcal/mol, -6 kcal/mol, respectively. Surprisingly, NCoR ID1a encouraged the 
ligand binding of each ligand; the energy bonus was within the range of 9 kcal/mol (ANDR) to 
1.45 kcal/mol (EE2). 
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Figure 16. The energy differences (EI-EII-IX) that calculated by energy values of the comparison 
group, system I (EI) deduct that of systems II-IX (EII-IX). The energy values are from E9ns of each 
MD simulation. For example, the energy value of CITCO in system I at 9
th
 ns of MD (-46.73 
Kcal/mol) deduct the energy value of CITCO in the presence of SRC-1 NR3 (-35.7 Kcal/mol), 
yielded -11 Kcal/mol energy differences. When value is positive, the ligand-protein binding 
energy is suggested to be more favorable in the presence of specific co-regulator peptides. But 
when the value is negative, the existing co-regulator peptides might destabilize the interaction 
between ligand and LBP of hCAR-LBD. 
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4 Conclusions 
 
This study analyzed the preference of multiple co-regulator motifs to interact with hCAR. 9 MD 
simulation systems were constructed, with special interest in the structural changes of hCAR-
LBD during the interaction with co-regulator motifs and ligands. These tested motifs included 3 
classes, namely (1) ID1 (including ID1a and ID1b) and ID2 of co-repressor NCoR; (2) NR1-3 
boxes of co-activator SRC-1; (3) NR1-2 boxes of TRAP. The ligands included 7 agonists and 8 
inverse agonists. The stability analysis suggested that these systems are stable enough to simulate 
the structural changes of hCAR complexes during the interaction. Moreover, the modeled 
structure changes are comparable with experimental data for MD systems with ID2 of NCoR, 
NR1 and NR2 of SRC-1, respectively. However, due to the complexity of the in vitro and in vivo 
conditions, further studies are needed to verify and improve the model reliability. 
Based on the results of this study, in co-regulator-motif class (1), the binding preference of ID2 
seemed to be higher than ID1. This was deducted from several observations: (1) under the 
influence of ID2, H12 moved out of the active position in the presence of inverse agonists; (2) 
peptide containing ID2 was stabilized in 3-turn helical conformation; (3) the binding was 
enhanced between peptide and hCAR-LBD by the approaching of the core residues of ID2 
towards the groove. In addition, the two homology models of ID1 (ID1a and ID1b) that were 
based on alternative sequence alignments, exhibited distinct structural features. Therefore, it 
would be interesting to discuss how the different structures of co-regulator motifs could relate to 
their activities; which one is more correct alignment.  
The structural changes intrigued by NR boxes of SRC-1, co-regulator-motif class (2), were less 
pronounced compared to that of co-regulator-motif class (1). These NR boxes tended to maintain 
the active state of H12 of hCAR-LBD. However, among these NR boxes, the ligand-protein 
interaction energy was less favorable in the presence of NR3 compared with NR1 and NR2. 
Therefore, the interaction of NR1 and NR2 with hCAR-LBD is probably stronger than with NR3. 
Several features in the interactions involving NR1 and NR2 were evident: (1) NR1 was found to 
enhance the stability of HX and this is in line with the study of Wright et al (2011), which proved 
the importance of HX stability for hCAR activation upon agonist binding; (2) NR2 induced clear 
differences between liganded structures of agonists and inverse agonists: H12 remained in active 
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position in the presence of agonist, but moved out of the active position in the presence of inverse 
agonists. Such differences were not seen in the case of NR1 and NR3.  
In co-regulator-motif class (3), the NR1 motif of TRAP may be not favored in the interaction 
with hCAR because the peptide was seen to depart away from the co-regulator groove.  TRAP 
NR2, on the other hand, may interact with hCAR in a ligand-independent manner, since NR2 
bound to the groove of liganded structures in similar manner as in the apo-structure.  
However, the major deficiency in this study probably was that all the peptides except one (SRC-1 
NR2) were based on the homology modeling. Thus the modeled peptides may disagree with the 
real structures and influence the performance of this model. For instance, the crystal structure of 
NCoR ID1 peptide that has been co-crystallized with Rev-erba (Phelan et al., 2010) is dissimilar 
to the homology models in this study. There are also many ligands that bind to hCAR with low 
affinity, which bring difficulties to rationalize the structural changes of hCAR caused by of 
ligand binding. The solving of additional x-ray crystal structures of hCAR and co-regulator 
peptides, the finding of more potent ligands and the acquiring of in vitro data for more hCAR/co-
regulator interactions, would enable the further validation of the model. 
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Appendix I. Structure information of ligands. 
 
 
  
Agonist Structure Inverse 
agonist 
Structure 
CITCO 
C19H12Cl3N3OS 
 
EE2 
C20H24O2 
 
FL82 
C16H15NO  
Androstanol 
C19H32O  
FL81 
C18H19NO3 
 
ANDR 
C19H30O 
 
Permethrin 
C21H20Cl2O3 
 
PK11195 
C21H21ClN2O 
 
CLOTR 
C22H17ClN2 
 
S07662 
C16H16N2O2S 
 
TPP 
C18H15O4P 
 
Clomifene 
C26H28ClNO 
 
Artemisin 
C15H18O4 
 
Celecoxib 
C17H14F3N3O2S 
 
  Meclizine 
C25H27ClN2 
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Appendix II. Root mean square deviations (RMSD) of the alpha carbon atoms of hCAR-LBD 
during 10 ns MD simulations 
 
Figure 1. RMSD of system I in the presence of (A) agonists and (B) inverse agonists.  
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Figure 2. RMSD of system II in the presence of (A) agonists and (B) inverse agonists.  
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Figure 3. RMSD of system III in the presence of (A) agonists and (B) inverse agonists.  
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Figure 4. RMSD of system IV in the presence of (A) agonists and (B) inverse agonists. 
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 Figure 5. RMSD of system V in the presence of (A) agonists and (B) inverse agonists.   
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Figure 6. RMSD of system VI in the presence of (A) agonists and (B) inverse agonists. 
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Figure 7. RMSD of system VII in the presence of (A) agonists and (B) inverse agonists.   
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Figure 8. RMSD of system VIII in the presence of (A) agonists and (B) inverse agonists.  
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 Figure 9. RMSD of system IX in the presence of (A) agonists and (B) inverse agonists.   
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Appendix III. The atomic positional fluctuation (APF) values of the hCAR-LBD backbone 
atoms 
 
Figure 1. APF values of system I in the presence of (A) agonists and (B) inverse agonists. 
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Figure 2. APF values of system II in the presence of (A) agonists and (B) inverse agonists.   
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Figure 3. APF values of system III in the presence of (A) agonists and (B) inverse agonists.  
 
Figure 4. APF values of system IV in the presence of (A) agonists and (B) inverse agonists.   
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 Figure 5. APF values of system V in the presence of (A) agonists and (B) inverse agonists.  
 
Figure 6. APF values of system VI in the presence of (A) agonists and (B) inverse agonists.  
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Figure 7. APF values of system VII in the presence of (A) agonists and (B) inverse agonists.  
Figure 8. APF values of system VIII in the presence of (A) agonists and (B) inverse agonists.   
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 Figure 9. APF values of system IX in the presence of (A) agonists and (B) inverse agonists.  
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Appendix IV. APF values of the C-terminal residues of hCAR-LBD  
 
 Figure 1. APF values of the C-terminal residues of hCAR-LBD in system I. (A) agonists. B) 
inverse agonists. 
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Figure 2. APF values of the C-terminal residues of hCAR-LBD in system II. (A) agonists. B) 
inverse agonists. 
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Figure 3. APF values of the C-terminal residues of hCAR-LBD in system III. (A) agonists. B) 
inverse agonists. 
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Figure 4. APF values of the C-terminal residues of hCAR-LBD in system IV. (A) agonists. B) 
inverse agonists. 
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 Figure 5. APF values of the C-terminal residues of hCAR-LBD in system V. (A) agonists. B) 
inverse agonists. 
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Figure 6. APF values of the C-terminal residues of hCAR-LBD in system VI. (A) agonists. B) 
inverse agonists. 
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 Figure 7. APF values of the C-terminal residues of hCAR-LBD in system VII. (A) agonists. B) 
inverse agonists. 
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Figure 8. APF values of the C-terminal residues of hCAR-LBD in system VIII. (A) agonists. B) 
inverse agonists. 
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Figure 9. APF values of the C-terminal residues of hCAR-LBD in system IX. (A) agonists. B) 
inverse agonists. 
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Appendix V. Helical content (HC %) (% of the MD time when the residues stay in helical 
conformation) of the C-terminal residues of hCAR-LBD 
 
 
Figure 1. HC % values of system I that are in the presence (A) agonists and (B) inverse agonists. 
The C-terminal residues that are shown in x axis (amino acids: 327-348) include three helices, 
H10 (amino acids 327-332), HX (amino acids 336-339) and H12 (amino acids 341-347). 
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Figure 2. Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System II that are in the presence of (C) agonists and (D) inverse agonists. 
 
Figure 3. Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System III in the presence of (A) agonists and (B) inverse agonists.  
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Figure 4. Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System IV in the presence of (A) agonists and (B) inverse agonists. 
 
Figure 5. Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System V in the presence of (A) agonists and (B) inverse agonists.  
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Figure 6. Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System VI in the presence of (A) agonists and (B) inverse agonists.  
 
Figure 7. Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System VII in the presence of (A) agonists and (B) inverse agonists.  
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Figure 8: Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System VIII in the presence of (A) agonists and (B) inverse agonists. 
 
Figure 9: Helical content (HC %) of the C-terminal residues of hCAR-LBD during MD 
simulations. System IX in the presence of (A) agonists and (B) inverse agonists.  
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Appendix VI. The binding of apo-hCAR with co-regulator peptides 
 
Figure 1. The binding of hCAR with co-repressor peptides. (A) NCoR ID2 binding, with 
showing the important residues of L1, I5 and L9 (boldface) of co-regulator peptides. (B) NCoR 
ID1a binding, with showing residues L1, I5 and I9 (boldface). (C) NCoR ID1b binding, with 
showing residues I1, I4 and I5 (boldface). Molecular surface (green) of hCAR-LBD are depicated 
in both transparent (right) and opaque (right) view. The ribbon that represent hCAR-LBD atoms 
is colored according to the secondary structure: α helix in red, β sheet in blue, others in pink or 
yellow. NCoR ID2, ID1a and ID1b peptides are shown in blue ribbon.   
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Figure 2. The co-regulator groove of hCAR with peptides from co-activator SRC-1. The 
important residues of L1, L4 and L5 (boldface) of peptides are shown. (A) NR1, (B) NR2 and 
(C)NR3 peptide binds onto apo-structure. The molecular surface of hCAR-LBD is shown in 
green, SRC-1 peptides is shown in blue. 
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Figure 3. The co-regulator groove of hCAR with peptides from mediator TRAP. The important 
residues of L1, L4 and L5 (boldface) of peptides are shown. (A) NR1, (B) NR2 peptide binds 
onto apo-structure. The molecular surface of hCAR-LBD is shown in green, SRC-1 peptides is 
shown in blue. 
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Appendix VII. The core residues co-regulator peptides on the liganded structures 
 
Figure 1. The core residues L1, I5 and I9 of NCoR ID1a on the liganded structures (cyan), 
compared to the apo-structure (blue).  
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Figure 2. The core residues I1, I4 and I5 of NCoR ID1b on the liganded structures (cyan), 
compared to the apo-structure (blue).  
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Figure 3. The core residues L1, L4 and L5 of SRC-1 NR1 on the liganded structures (cyan), 
compared to the apo-structure (blue).  
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Figure 4. The core residues L1, L4 and L5 of SRC-1 NR2 on the liganded structures (cyan), 
compared to the apo-structure (blue). 
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Figure 5. The core residues L1, L4 and L5 of SRC-1 NR3 on the liganded structures (cyan), 
compared to the apo-structure (blue).   
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Appendix VIII. Helical content (HC %) of the co-regulator peptides during MD 
simulations
 
Figure 1. Helical content (HC %) of the peptide from co-repressor NCoR during MD 
simulations. (A) NCoR ID2 in system II and (B) NCoR ID1a in system III and (C) NCoR ID1b in 
system IV.  
104 
 
 
 Figure 2. Helical content (HC %) of peptides from co-activator SRC-1 during MD simulations. 
(A) NR1 in system V and (B) NR2 in system VI and (C) NR3 in system VII.  
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Figure 3. Helical content (HC %) of the peptide from TRAP during MD simulations. (A) TRAP 
NR1 in system VIII and (B) TRAP NR2 in system IX.  
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Appendix IX. Positions of H12 in the final structures from 10 ns MD simulations 
 
Figure 1. Positions of H12 in system I in the presence of (A) agonists and (B) inverse agonists. 
Apo (transparent, blue) is shown as a reference with each liganded structure (cyan). 
Figure 2. Positions of H12 in system V in the presence of (A) agonists and (B) inverse agonists. 
Apo (transparent, blue) is shown as a reference with each liganded structure (cyan).  
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Figure 3. Positions of H12 in system VI in the presence of (A) agonists and (B) inverse agonists. 
Apo (transparent, blue) is shown as a reference with each liganded structure (cyan). 
Figure 4. Positions of H12 in system VII in the presence of (A) agonists and (B) inverse 
agonists. Apo (transparent, blue) is shown as a reference with each liganded structure (cyan). 
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Figure 5. Positions of H12 in system VIII in the presence of (A) agonists and (B) inverse 
agonists. Apo (transparent, blue) is shown as a reference with each liganded structure (cyan). 
Figure 6. Positions of H12 in system IX in the presence of (A) agonists and (B) inverse agonists. 
Apo (transparent, blue) is shown as a reference with each liganded structure (cyan). 
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Appendix X. The helical content (% of MD simulation time when HX was stabilized in helical 
conformation) of HX 
 
a
agonist*; inverse agonist** 
  
Ligand
a
 
System 
I II III IV V VI VII VIII IX 
APO 83 44 73 41 71 62 58 86 79 
CITCO* 55 64 41 70 86 66 75 46 65 
FL82* 35 75 69 50 85 85 55 65 77 
FL81* 71 57 69 53 74 47 76 76 66 
Permethrin* 48 37 30 52 78 65 63 70 60 
CLOTR* 59 51 47 66 73 54 74 74 76 
TPP* 58 65 71 49 85 51 77 68 67 
Artemisin* 59 24 30 50 66 71 22 62 70 
EE2** 65 68 66 37 53 65 59 69 75 
Androstanol** 60 39 21 26 47 39 65 64 52 
ANDR** 69 33 29 5 75 71 41 57 69 
PK11195** 67 43 29 34 38 61 78 71 52 
S07662** 64 61 48 46 77 79 71 54 64 
Clomifene** 61 52 43 66 35 42 36 89 68 
Celecoxib** 31 48 37 55 51 70 39 44 37 
Meclizine** 51 61 48 46 68 59 64 75 80 
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Appendix XI. APF values of the H2-H3 loop of hCAR-LBD 
 
Figure 1. APF values of the H2-H3 loop of hCAR-LBD of system I in the presence of (A) 
agonists and (B) inverse agonists. 
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Figure 2. APF values of the H2-H3 loop of hCAR-LBD of system II in the presence of  (A) 
agonists and (B) inverse agonists. 
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Figure 3. APF values of the H2-H3 loop of hCAR-LBD of system III in the presence of  (A) 
agonists and (B) inverse agonists. 
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Figure 4. APF values of the H2-H3 loop of hCAR-LBD of system IV in the presence of  (A) 
agonists and (B) inverse agonists.  
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Figure 5. APF values of the H2-H3 loop of hCAR-LBD of system V in the presence of  (A) 
agonists and (B) inverse agonists.  
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Figure 6. APF values of the H2-H3 loop of hCAR-LBD of system VI in the presence of  (A) 
agonists and (B) inverse agonists. 
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Figure 7. APF values of the H2-H3 loop of hCAR-LBD of system VII in the presence of  (A) 
agonists and (B) inverse agonists. 
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Figure 8. APF values of the H2-H3 loop of hCAR-LBD of system VIII in the presence of  (A) 
agonists and (B) inverse agonists. 
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Figure 9. APF values of the H2-H3 loop of hCAR-LBD of system IX in the presence of  (A) 
agonists and (B) inverse agonists. 
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Appendix XII. The ligand-protein interaction energy that were calculated with MM-PBSA 
method. CITCO, meclizine, clomifene and permethrin who have the highest molecular weight, 
gain the most favorable energy values. 
  
 
